CA2661332A1 - Compositions and methods for diagnosis and treatment of type 2 diabetes - Google Patents

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes (Figure 21).

Description

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT

FIELD OF THE INVENTION
The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such =biological markers in diagnosis and prognosis of Diabetes. Furthermore, selected biological markers of the present invention present new targets for therapy and constitute new therapeutics for treatment or prevention of Diabetes_ BACKGROUND OF THE INVENTION
Diabetes mellitus comprises a cluster of diseases distinguished by chronic hyperglycemia that result from the body's failure to produce and/or use insulin, a hormone produced by (3-cells in the pancreas that plays a vital role in metabolism. Symptoms include increased thirst and urination, hunger, weight loss, chronic infections, slow wound healing, fatigue, and blurred vision. Often, however, symptoms are not severe, not recognized, or are absent. Diabetes can lead to debilitating and life-threatening complications including retinopathy Ieading to blindness, memory loss, nephropathy that may lead to renal failure, cardiovascular.
disease, neuropathy, autonomic dysfunction, and limb amputation. Several.pathogenic processes are involved in the development of Diabetes, including but not limited to, processes which destroy the insulin-secreting P-cells with consequent insulin deficiency, and changes in liver and smooth muscle cells that result in resistance to insulin uptake. Diabetes can also eomprise abnormalities of carbohydrate, fat, and protein metabolism attY"ibuted to the deficient action of insulin on target tissues resulting from insulin insensitivity or lack-of itisulin.
Type 2 Diabetes is the most common form of Diabetes, which typically develops as a result of.a relative, rather than absolute, insulin deficiency, in combination with the body's failure to use insulin properly (also known in the art as "insulin resistance"). Type 2 Diabetes often manifests in persons, including children, who are overweight; other risk factors include high cholesterol, high blood pressure, ethnicity, and genetic factors, such as a family history of Diabetes. The majority of patients with Type 2 Diabetes are obese, and obesity itself may cause or aggravate insulin resistance_ Apart from adults, an increasing number of children are also being diagnosed with Type 2 Diabetes. Due to the progressive nature of the disease, Diabetes complications often develop by the time these children become adults. A study by the American Diabetes Association (ADA) involved 51-children that were diagnosed with Diabetes before the age of 17. By the time these children reached their early 30s, three had kidney failure, one was blind, and two died of heart attacks while on dialysis. This study reinforces the severity of the disease, the serious damage inflictedby.Diabetes complications, and the need for early diagnosis of the disease.
The incidence of Diabetes has been rapidly escalating to alarming numbers.
Diabetes currently affects approximately 170 nlillion people worldwide with the World Health Organization (WHO) predicting 300 znillion diabetics by 2025. The United States alone has 20.8 rnillion people suffering from Diabetes (approximately 6% of population and the 6th most common cause of death). The annual direct healthcare costs of. Diabetes worldwide for people in the 20-79 age bracket are estimated at $153-286 billion and is expected to rise to $2I3-396 billion in 2025.
Along with the expansion of the diagnosed diabetic population, the undiagnosed diabetic population has also continued to increase, primarily because Type 2 Diabetes is often asymptomatic in its early stages, or the hyperglycemia is often not severe enough to provoke noticeable symptoms of Diabetes. It is believed that approximately 33% of the 20.8 million diabetics in the United States remain undiagnosed. Due to the delay in diagnosis, Diabetes complications have already advanced and thus, the future risk of further complication and derailment is severely increased = To obviate complications and irreversible damage to multiple organs, Diabetes management guidelines advocate initiation of therapeutic intervention early in the prognosis of the disease.
This modern epidenaic requires new tools for early detection of'T'ype 2 Diabetes, before the disease instigates significant and irreparable damage. In addition, new treatment paradigms are needed to halt, delay, or ameliorate the massive deterioration in patient health, ideally reversing the course of the disease to partial or complete cure as an alternative or a substitute for current treatments, which merely address chronic management of disease symptorns. Diabetic hyperglycemuia can be decreased by weight reduction, increased physical activity; and/or therapeutic treatment modalities. Several biological mechanisms are associated with hyperglycemia, such as insulin resistance, insulin secretion, and gluconeogenesis, and there are several agents available that act on one or more of these mechanisms, such as but not linuted to metfonnin, acarbose, and rosiglita.zone.
It is well documented that the pre-diabetic state can be present for ten or more years before the detection of glycemic disorders like Diabetes. Treatment of pre-diabetics with therapeutic agents can postpone or prevent Diabetes; yet few pre-diabetics are identified and treated. A major reason, as indicated above, is that no simple laboratory test exists to deterrrune the actual risk of an individual to develop Diabetes. Thus, there remains a need in the art for methods of identifying and diagnosing these individuals who are not yet diabetics, but who are at significant risk of developing Diabetes.
SUMMAR3.' OF THE INVENTION
The present invention is premised on the discovery that disease-associated biomarkers can be identified in serum or other bodily fluids long before overt disease is apparent. The presence or absence of these biomarkers from the serum footprints of patients suffering from Type 2 Diabetes precede disruptions in blood glucose control and can be used as early diagnoSric tools, for which treatment strategies can be devised and administered to prevent, delay, ameliorate, or reverse irreversible organ damage. One or several of the disease-associated biomarkers of the present invention can be used to diagnose subjects suffering from Type 2 Diabetes or related diseases, or advantageously, to diagnose those subjects who are asymptomatic for Type 2 Diabetes and related diseases. The biomarkers of the present inventiQn can also be used for the design of new therapeutics. For instance, a biomarker absent in a diabetic patient and found in a healthy individual can constitute a new protective or therapeuti"c agent which, upon administration to the patient, may alleviate symptoms or even reverse_the disease.
Accordingly, in one aspect, the present invention provides a method of diagnosing or identifying type 2 Diabetes or a pre-diabetic condition in a subject, corrrprising measuring an effective amount of one or more DBMARKERS or a metabolite thereof in a sample from the subject, and comparing the amount to a reference value, wherein an increase or decrease in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from the type 2 Diabetes or the pre-diabetic condition.
In one embodiment, the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a.
pre-diabetic condition.
In another embodiment, the decrease is at least 10% greater than the reference value. In other embodiments, the increase is at least 10% greater than the reference value.
The sample can be urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.
The DBMARKERS oÃthe present invention can be detected electrophoretically, immunochemically, by proteomics technology, or:by=genomic analysis. The immunochemical detection can be radioimmuno assay, immunoprecipitation, irnmunoblotting, immunofluorescence assay, or enzyme-linked immunosorbent assay. The proteomics technology can comprise SELDI, MALDI, LC/MS, tandem LC/MS/MS, protein/peptide arrays, or antibody arrays. The genomic analysis can comprise polymerase chain reaction (PCR), real-time PCR, rnicroarray analysis, Northern blotting, or Southern blotting.
In another embodiment, the subject has not been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition. The subject can also be one who has been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition.
Alternatively, the subject can be asymptomatic for the type 2 Diabetes or the pre-diabetic condition.
Another aspect of the present invention provides a method for monitoring the progression of type 2 Diabetes or a pre-diabetic condition in a subject, comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject at- a second period of time, and (c) comparing the amounts of the one or more DBMARKER.S detected in step (a) to the amount detected in step (b), or to- a reference value.
In one embodiment, the subject has previously been treated for the type 2 Diabetes or the pre-diabetic condition. In another embodiment, the first sample is taken from the subject prior to being treated for the type 2 Diabetes or the pre-diabetic condition. The second sample can be taken from the subject after being treated for the type 2 Diabetes or the pre-diabetic condition. In other.embodiments, the treatment for the type 2 Diabetes or the pre-diabetic condition.comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof. The progression of type 2 Diabetes or pre-diabetic conditions can be monitored by detecting changes in body mass index (BMI), insulin levels, blood glucose levels, HDL levels, systolic and/or diastolic blood pressure, or combinations thereof.

In another aspect of the present invention, a method of monitoring the effectiveness of a treatment regimen for type 2 Diabetes or a pre-diabetic condition in a subject is provided, comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject prior to treatment of the type 2 Diabetes or the pre-diabetic condition, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject after treatment of the type 2 Diabetes or the pre-diabetic condition, and (c) comparing the amount of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value. In one embodiment, changes in blood glucose levels can be detected by oral glucose tolerance test_ Yet another aspect of the present invention provides a method of treating a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, comprising detecting an effective amount of one or more DBIv1ARKERS or metabolites thereof present in a first sample from the subject at a first period of time, and treating the subject with one or more diabetes-modulating agents until the amounts of the one or more DBMARKERS or metabolites thereof return to a reference value measured in one or more subjects at low risk for -developing type 2 Diabetes or a pre-diabetic condition, or a reference value measured in one or more subjects who show improvements in Diabetes risk factors as'a result of treatment with the one or more diabetes-modulating agents.
In one embodiment, the one or more diabetes-modulating agents comprise sulfonylureas, biguanides, insulin, insulin analogs, peroxisome prolifereator-activated receptor-y (PPAR-y) agonists, dual-acting PPAR agonists, insulin secretagogues, analogs of glucagon-like peptide-1 (GLP-1), inhibitors of dipeptidyl peptidase IV, pancreatic lipase inhibitors, a-glucosidase inhibitors, or combinations thereof. In another embodiment, the improvements in Diabetes risk factors as a result of treatment with one or more diabetes-modulating agents comprise a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.
In another aspect of the present invention, a method of selecting a treatment regimen for a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition is provided, comprising (a) detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time, and comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value. In one embodiment, the reference value is derived from one or more subjects who show an improvement in Diabetes risk factors as a result of one or more treatments for type 2 Diabetes or the pre-diabetic condition.
Another aspect of the present invention provides a method of evaluating changes in the risk of developing type 2 Diabetes or a pre-diabetic condition in a subject, comprising (a) detecting an effective amount of one or more DBIVIARKERS in a first sample from the subject at a first period of time, (b) detecting an effective amount of one or more DBMARY-ERS in a second sample from the subject at a second period of time, and comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.
In another aspect, a method of identifying one or more complications related to type 2 Diabetes'in a subject is provided, comprising measuring an effective amount of one or more DBMARKERS or a metabolite thereof iri a sample from the subject and comparing the amount to a reference value, wherein an increase or decrease 'in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from or is at risk for developing complications related to type 2 Diabetes.
In one embodiment, the complications comprise retinopathy, blindness, memory loss, nephropathy, renal failure, cardiovascular disease, neuropathy, autonomic dysfunction, hyperglycemic hyperosmolar coma, or combinations thereof. In another embodiment, the reference value comprises an index value, a value derived from one or more diabetes risk-prediction algorithms or computed indices, a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a value derived from a subject previously identified as having one or more complications related to type 2 Diabetes.
Another aspect of the present invention provides a type 2 Diabetes reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS
detected in one or more subjects who are not diagnosed with or identified as sufering from type 2 Diabetes. In another aspect, the present invention provides a pre-diabetic condition reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS
detected in one or more subjects who are not diagnosed with or identified as suffering from a pre-diabetic condition. The invention also provides a type 2 Diabetes subject expression profile, comprising a pattern, of expression levels detected in one or more subjects diagnosed with or identified as suffering from type 2'Diabetes, are at risk for developing type 2 Diabetes, or are being treated for type 2 Diabetes. In another aspect, the present invention also provides a pre-diabetic condition subject expression profile, comprising a pattern of expression levels detected in one or more subjects diagnosed with or identified as suffering from a pre-diabetic condition, are at risk for developing a pre-diabetic condition, or are being treated for a pre-diabetic condition.
The present invention also provides a kit comprising DBMARKER detection reagents that detect one or more DBMARKERS; a sample derived from a subject having normal glucose levels, and optionally instructions. for using the reagents to generate the expression profiles disclosed herein. The detection reagents can be, for example, one or more antibodies or fragments thereof, one or more aptamers, one or more oligonucleotides, or combinations thereof.
In another aspect of the present invention, a pharmaceutical composition for treating type 2 Diabetes or a pre-diabetic condition in a subject is provided, conmprising a therapeutically effective amount of one or more DBMARKERS or a metabolite thereof, and a pharmaceutically acceptable carrier or diluent. In some embodiments, the DBnRARKER metabolite comprises SF3Q ID NO: 1. In other embodiments, the DBMARKER metabolite comprises at least 5, at least 10, at least 15, or at least 20 contiguous amino acid residues of SEQ ID NO:
1. Alternatively, the DBMARKER metabolite can comprise an amino acid 'sequence at least 90%
identical to SEQ
IDNO: 1.
The present invention also provides a pharmaceutical composition consisting essentially of SEQ ID NO: 1 and a pharmaceutically acceptable carrier or diluent.
In yet another aspect, a method of treating type 2 Diabetes or a pre-diabetic condition in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of the pharmaceutical compositions of the invention.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, suitable methods and materials are described below.
All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety. In cases of conflict, the present specification, including definitions, will control. In addition, materials, methods, and examples described herein are illustrative.only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from and are encompassed by the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS
The following Detailed Description, given by way of example, but not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying Figures, incorporated herein by reference, in which:
: Figure 1 represents a protein expression profile of pancreatic-extracts from Cohen diabetic resistant (CDr) and sensitive (CDs) rats fed regular diet (RD) or copper-poor high-sucrose diet (HSD). Total protein extract (5 g) was prepared under reducing conditions and run on a 4-12% polyacrylamide gel.
Figure 2A is a graphical comparison of serum samples from CDr-RD, CDs-RD, CDr-HSD, and CDs-HSD on a SELDI QI0 anion exchange surface chip. A median peak is present in CDr-RD and CDr-HSD (marked by an arrow), but not in CDs-RD and CDs-HSD. A
protein fragment from this differentially expressed peak was identified as the C-ternii.nal fragment of Serpina 3M. -Figure 2B is an MS/MS spectrum of the 4.2 kilodalton fragment identified by SELDI.
Figure 3A depicts a BLAST alignment of the 38-amino acid Serpina 3M (also referred to as "D3") peptide and.proteins identified as having similar sequence identity.
Figure 3B shows a BLAST alignment of nucleic acid sequences encoding the 38-amino acid Serpina 3M peptide and proteins identified in 3A.
Figure 3C is a photograph of an agarose gel displaying the results of an RT-PCR
experiment using degenerate primers designed to detect the conserved amino acid motifs found in the BLAST alignments of Figures 3A and 3B.
Figure 4A. is a photograph of two-dimensional maps of CDr-RD, CDs-RD, CDr-HSD
and CDs-HSD serum samples analyzed by the 2D/LC fractionation system. The intensity of the blue bands represents the relative protein amount as detected at 214 nm by LN
absorbance.
Figure 4B shows a differential second-dimensional reverse-phase HPLC elution profile of CDr-RD (red) versus CDs-RD (green) of a selected first-dimensional isoelectric point fraction (Fraction 31). Proteins that were uniquely identified in CDs-RD samples are listed at the bottom of the graph.

Figure 5A is a photograph of a protein gel representing differential protein profiling of CD rat serum samples using two-dimensional gel electrophoresis (2DE). The pH
for the first dimension chromatofocusing was from pH 5-8, and the second dimensional separation used a 4-20% Tris-HCI SDS-PAGE gel. The gel was stained with BioSafe Coomassie Staining (Bio-Rad) for visualization.
Figure 5B is a magnified view of the spots identified in Figure 5A.
Figure 6 comprises graphical representations illustrating differentially expressed proteins found in the Cohen Diabetic rat models using 2DE.
Figure 7 is a histogram depicting the differentially expressed Cohen Diabetic rat serum , proteins identified by 2DE.
Figure 8 is a photograph of Western blots depicting the reactivity of the D3-hyperimmune rabbit serurn with the -4kD protein fragment present in CDr-RD and CDr-HSD rat serum. In the left photograph, a higher molecular weight doublet (in the range of 49 and 62 kD) also reacted with the hyperimmune sera, indicating that a parent protein (and a protein complex) is expressed by all strains under both RD and HSD treatment modalities, while the derivative of smaller size is differentially expressed only in the CDr strain. As a negative control, the right photograph shows a Western blot membrane incubated in the absence of the D3 hyperimmune rabbit serum.
Figure 9 depicts the concentration of the D3 peptide in CDr rat serum as calculated from SELDI analysis.
Figure 10 are photographs of gels containing liver extracts (10 g), which was probed with secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (HRP)(1:25000 dilution), in the presence (right panel) or absence (left panel) of primary anti-D3 serum antibody (1:200 dilution).
Figure 11 is a photograph of a Western blot analyzing human sera using D3 hyperimmune serum from rabbits. Lane 1 corresponds to the molecular weight marker. Lanes 2-7 represent fractions of a single serum sample from a normal individual (3045 NGT). Lanes 10-14 represent fractions of a single serum sample from a Type 2 Diabetes patient (291).
Figures 12A and 12B show preparative gels that were run with. 100 g of CDr-HSD and CDs-HSD pancreatic extracts, respectively. The positive control was stained with 20 g of anti-actin antibody, and the subclone lanes were stained with 600 l of conditioned culture supematant.

Figure 13 depicts the results of whole human serum profiled on an anionic Q10 protein chip by SELDI.
Figure 14 is a photograph of a pseudogel showing the differentially expressed protein peaks identified in 13 T2D and 16 normal human serum samples. For the Ml2 15.2 kD marker, the average peak intensity for T2D samples was 2.6, while for normal samples, the average peak intensity was 22.2. The difference between the two samples was about 9-fold.
For the M1Z 14.8 kD=marker, the average intensity for T2D samples was 4.4, and the average intensity for normal samples was 3.3. The relative intensity ratio was 1.47.
Figure 15 is a photograph of a pseudogel showing the differentially expressed protein peaks identified in 13 T2D and 16 normal human serum samples. The average peak intensity for T2D samples was 118, while for normal samples, the average peak intensity was 182. The ratio of relative intensity was 0.65. Each dot represents the intensity of the protein peak measured in individual samples.
:. Figure 16 are graphs depicting differential albumin profiling in samples obtained from obese T2D subjects (Dr. Cheatham's samples) vs. non-obese T2D subjects (Dr.
Dankner's samples).
Figures 17A and 17B are graphical representations of ELISA reactivity of CDs-HSD and CDr-HSD specific hybridoma colonies, as measured by absorbance at O.D. 450 rim.
Figures 18A, 18B, and 18C are photographs of Western blots depicting the reactivity of = the CDs-HSD and CDr-HSD specific hybridoma clones P2-10-B8-KA8, PI-14-A2-E-H8, P2-4-H5-K-B4, P1-20-B7-F-C1, P2-13-A9-P-A8, and P1-5-F11-XF5.
. Figure 19 is a photograph of a Coomassie-stained SDS-polyacrylamide gel following immunoprecipitation with the specific hybridoma clones derived from CDs-HSD
and CDr-HSD.
Figure 20A and 20B are screenshots of an MS spectrum analysis of the lower bands excised from the SDS-PAGE gel in Figure 18. A positive identification of the lower band as calnexin was made.
Figure 21 is a scatter plot of the 137 differentially expressed genes in Cohen Type 2 Diabetes rat pancreas. Both upregulated and downregulated genes are shown on the plot.
Figure 22A depicts Gene Tree microarray analysis of 12,729 genes present in Cohen Type 2 Diabetes rat pancreas.

Figure 22B depicts Gene Tree microarray analysis of the 820 genes that were found to have 2-fold changes in expression, and the 137 genes shown to have 3-fold changes in expression in Cohen Type 2 Diabetes rat pancreas.
Figure 22C depicts the Sets 1-5 of the 137 genes exhibiting 3-fold changes in expression, as classified by K-mean clustering.

DETAILED DESCt2IPTION OF THE INVENTION
The present invention relates to the identification of biomarkers associated with subjects having Diabetes or a pre-diabetic condition, or who are pre-disposed to developing Diabetes or a pre-diabetic condition. Accordingly, the present invention features diagnostic and prognostic methods for"identifying subjects who are pre-disposed to developing Diabetes or a pre-diabetic condition, including those subjects who are asymptomatic for Diabetes or a pre-diabetic condition by detection of the biomarkers disclosed herein. The biomarkers can also be used advantageously to identify subjects having or at risk for developing complications relating to Type 2 Diabetes. These biomarkers are also useful for monitoring subjects undergoing treatments and therapies for Diabetes or pre-diabetic conditions, and for selecting therapies and treatments that would be effective in subjects having Diabetes or a pre-diabetic condition, wherein selection and use of such treatments and therapies slow the progression of Diabetes or pre-diabetic conditions, or substantially delay or prevent its onset. The biomarkers of the present invention can be in the form of a pharmaceutical composition used to treat subjects having type 2 Diabetes or related conditions.
As used herein, "a," an" and "the" include singular and plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an active agent"
or "a pharmacologically active agent" includes a single active agent as well as two or more different active agents in combination, reference to "a carrier" includes mixtures of two or more carriers as well as a single carrier, and the like.
"Diabetes Mellitus" in the context of the present invention encompasses Type 1 Diabetes, both autoimmune and idiopathic and Type.2 Diabetes (together, "Diabetes"). The World Health Organization defines the diagnostic value of fasting plasma glucose concentration to 7.0 mmol/1 (126 mg/dl) and above for Diabetes Mellitus (whole blood 6.1 mmol/l or 110 mg/dl), or 2-hour glucose level >_11.1 mmol/L (?200 mg/dL). Other values suggestive of or indicating high risk for Diabetes Mellitus include elevated arterial pressure _ 140/90 mm.Hg;
elevated plasma triglycerides (_1.7 mmol/L; 150 mg/dL) and/or low HDL-cholesterol (<0.9 mmol/L, 35 mg/dl for men; <1.0 mmol/L, 39 mg/dL women); central obesity (males: waist to hip ratio >0.90;
females: waist to hip ratio > 0.85) and/or body mass index exceeding 30 kg/m2;
microalbuminuria, where the urinary albumin excretion rate -2:20 g/min or albumin:creatinine ratio _ 30 mg/g).
A "pre-diabetic condition" refers to a metabolic state that is intermediate between normal glucose homeostasis, metabolism, and states seen in frank Diabetes Mellitus.
Pre-diabetic conditions include, without limitation, Metabolic Syndrome ("Syndrome X"), Impaired Glucose Tolerance (IGT), and Impaired Fasting Glycemia (IFG). IGT refers to post-prandial abnormalities of glucose regulation, while IFG refers to abnormalities that are measured in a fasting state. The World Health Organization defines values for IFG as a fasting plasma glucose concentration of 6.1 mmol/L (100 mg/dL) or greater (whole blood 5.6 mmol/L;
100 mg/dL), but less than 7.0 mmol/L (126 mg/dL)(whole blood 6.1 mmol/L; 110 mg/dL). Metabolic Syndrome according to National Cholesterol Education Program (NCEP) criteria are defined as having at least three of the following: blood pressure _130/85 mm Hg; fasting plasma glucose _6.1 mmol/L; waist circumference >102 cm (men) or >88 cm (women); triglycerides >_1.7 mmol/L;
and HDL cholesterol <1.0 mmol/L (men) or 1.3 mmol/L (women).
"Impaired glucose tolerance" (IGT) is defined as having a blood,glucose level that is higher than normal, but not high enough to be classified as Diabetes Mellitus.
A subject with IGT will have two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol) on the 75 g oral glucose tolerance test. These glucose levels are above normal but below the level that is diagnostic for Diabetes. Subjects with irnpaired glucose tolerance or impaired fasting glucose have a significant risk of developing Diabetes and thus are an im.portant target group for primary prevention.
"Insulin resistance" refers to a condition in which the cells of the body become resistant to the effects of insulin, that is, the normal response to a given amount of insulin is reduced. As a result, higher levels of insulin are needed in order for insulin to exert its effects. ' "Complications related to type 2 Diabetes" or "complications related to a pre-diabetic condition" can include, without limitation, diabetic retinopathy, diabetic nephropathy, blindness, memory loss, renal failure, cardiovascular disease (including coronary artery disease, peripheral artery disease, cerebrovascular disease, atherosclerosis, and hypertension), neuropathy, autononuc dysfunction, hyperglycemic hyperosmolar coma, or combinations thereof.

"Normal glucose levels" is used interchangeably with the term "normoglyceniic"
and refers to a fasting venous plasma glucose concentration of less than 6.1 mmol/L (110 mg/dL).
Although this amount is arbitrary, such values have been observed in subjects with proven normal glucose tolerance, although some may have IGT as measured by oral glucose tolerance test (OGTT). A baseline value, index value, or reference value in the context of the present invention and defined herein can comprise, for example, "normal glucose levels."
One hundred and fifty-eight (1.58) biomarkers have'been identified as having altered or modified presence or concentration levels in subjects who have Diabetes, or who exhibit symptoms characteristic of a pre-diabetic condition, such as those subjects who are insulin resistant, have altered beta cell function or are at risk of developing Diabetes based upon known clinical parameters or risk factors, such as fanlily history of Diabetes, low activity level, poor diet, excess body weight (especially around the waist), age greater than 45 years, high blood pressure, high levels of triglycerides, HDL cholesterol of less than 35, previously identified impaired glucose tolerance, previous Diabetes during pregnancy ("gestational Diabetes Mellitus") or giving birth to a baby weighing more than nine pounds, and ethnicity.
The biomarkers and methods. of the present invention allow one of skill in the art to identify, diagnose, or otherwise assess those subjects who do not exhibit any syinptoms of Diabetes or a pre-diabetic condition, but who nonetheless may be at risk for developing Diabetes or experiencing symptoms characteristic of a pre-diabetic condition.
The term "biomarker" in the context of the present invention encompasses, without limitation, proteins, peptides, nucleic acids, polymorphisms of proteins and nucleic acids, splice variants, fragments of proteins or nucleic acids, elements, metabolites, and other analytes.
Biomarkers can also include mutated proteins or mutated nucleic acids. The term "analyte" as used herein can mean any substance to be measured and can encompass electrolytes and elements, such as calcium. Finally, biomarkers can also refer to non-analyte physiological markers of health status encompassing other clinical characteristics such as, without limitation, age, ethnicity, diastolic and systolic blood pressure, body-mass index, and resting heart rate.
Proteins, peptides, nucleic acids, polymorphisms, and metabolites whose levels are changed in subjects who have Diabetes or a pre-diabetic condition, or are predisposed to developing Diabetes or a pre-diabetic condition are summarized in Table 1 and are collectively referred to herein as, inter alia, "Diabetes-associated proteins", "DBMARIr.ER
polypeptides", or "DBIVIARKER proteins". The corresponding nucleic acids encoding the polypeptides are referred to as "Diabetes-associated nucleic acids", "Diabetes-associated genes", "DBMARKER
nucleic acids", or "DBMARKER genes". Unless indicated otherwise, "DBMARKER", "Diabetes-associated proteins", "Diabetes-associated nucleic acids" are meant to refer to any of the sequences disclosed herein. The corresponding metabolites of the DBMARKER
proteins or nucleic acids can also be measured, herein referred to as "DBMA.RKER
metabolites".
Calculated indices created from mathematically combining measurements of one or more, preferably two or more of the aforementioned clas"ses of DBMA.RKERS are i=eferred to as "DBMAR.KER indices". Proteins, nucleic acids, polymorphisms, mutated proteins and mutated nucleic acids, metabolites, and other analytes are, as well as common physiological measurements and indices constructed from any of the preceding entities, are included in the broad category of "DBMARKERS".
One DBMARKER of interest, which has a molecular weight of about 4.2kD and was further identified as a C-terminal fiagment of a serine protease inhibitor, Serpina 3M. This marker was shown to be upregulated in CDr-RD and CDr-HSD rats. Amino acid sequencing of .15 this fragment revealed that this fragment comprises the amino acid sequence SGRPPMNWFNRPFLIAVSHTHGQTILFMAKVINPVGA (SEQ ID NO: 1) A DBMARKER "metabolite" in the context of the present invention comprises a portion of a full length polypeptide. No particular length is implied by the term "portion.'~ A
DBMARKER metabolite can be less than 500 amino acids in length, e.g., less than or equal to 400, 350, 300, 250, 200, 150, 100, 75; 50, 35, 26, 25, 15, or 10 amino acids in length. An exemplary DBMARKER metabolite includes a peptide, which can include (in whole or in part) the sequence of SEQ ID NO: 1. Preferably, the DBMARKER metabolite includes at least 5, 10, 15, 20, 25 or more contiguous amino acids of SEQ ID NO:1..

A"subject" in the context of the present invention is preferably a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of Diabetes Mellitus or pre-diabetic conditions. A
subject can be male or female. A subject can be one who has been previously diagnosed withor identified as suffering from or having Diabetes or a pre-diabetic condition, and optionally, but need not have already undergone treatment for the Diabetes or pre-diabetic condition. A
subject can also be one who is not stiffering from type 2 Diabetes or a pre-diabetic condition. A
subject can also be one who has been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, but who show improvements in known Diabetes risk factors as a result of receiving one or more treatments for type 2 Diabetes or the pre-diabetic condition. Alternatively, a subject can also be one who has not been previously diagnosed as having Diabetes or a pre-diabetic condition. For example, a subject can be one who exhibits one or.more risk factors for Diabetes or a pre-diabetic condition, or a subject who does not exhibit Diabetes risk factors, or a subject who is asymptomatic for Diabetes or a pre-diabetic condition. A
subject can also be one who is suffering from or at risk of developing Diabetes or a pre-diabetic condition. A subject can also be one who has been diagnosed with or identified as.having one or more complications related to type 2 Diabetes or a pre-diabetic condition as defined herein, or alternatively, 'a subject can be one who has not been previously diagnosed with or identified as having one or more complications related to type 2 Diabetes or a pre-diabetic condition.
A"saxnple" in the context of the present invention is a biological sample isolated from a subject and can include, for example, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, lymphatic fluid, pancreatic juice, ascites fluid, iriterstitital fluid (also known as "extracellular fluid" and encompasses the fluid found in spaces between cells, including, inter alia, gingival crevicular fluid), bone marrow, sputurn, saliva, tears, or urine.
One or more, preferably two or more DBIVIARK-ERS can be detected in the practice of the present invention. For example, one (1), two (2), five (5), ten (10), fifteen (15), twenty (20), twenty-five (25), thirty (30), thirty-five (35), forty (40), forty-five (45), fifty (50), fifty-five (55), sixty (60), sixty-five (65), seventy (70), seventy-five (75), eighty (80), eighty-five (85), ninety (90), ninety-five (95), one hundred (100), one hundred and five (105), one hundred and ten (110), one hundred and fifteen (115), one hundred and twenty (120), one hundred and twenty-five (125), one hundred and thirty (130), one hundred and thirty-five (135), one hundred and forty (140), one hundred and forty-five (145), one hundred and fifty (150), one hundred and fifty-five (155) or more DBMARKERS can be detected. In some aspects, all 158 DBMARKERS
disclosed herein can be detected. Preferred ranges from which the number of DBNIARK.ERS
can be detected include ranges bounded by any minimum selected from between one and 158, particularly two, five, ten, fifteen, twenty, twenty-five, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, one hundred and ten, one hundred and twenty, one hundred and thirty, one hundred and forty, one hundred and fifty, paired with any maximum up to the total known DBMARKERS, particularly one, two, five, ten, twenty, and twenty-five.
Particularly preferred ranges include one to two (1-2), one to five (1-5), one to ten (1-10), one to fifteen (1-15), one to twenty (1-20), one to twenty-five (1-25), one to tliirty (1-30), one to thirty-five (1-35), one to forty (1-40), one to forty-five (1-45), one to fifty (1-50), one to fifty-five (1-55), one to sixty (1-60), one to sixty-five (1-65), one to seventy (1-70), one to seventy-five (1-75), one to eighty (1-80), one to eighty-five (1-85), one to ninety (1-90), one to ninety-five (1-95), one to one hundred (1-100), one to one hundred and twenty (1-120), one to one hundred and twenty-five (1-125), one to one-hundred and thirty (1-130), one to one hundred and forty (1-140), one to one hundred and fifty (1450), one to one hundred and fifty-eight (1-158), two- to five (2-5), two to teri (2:-10), two to fifteen (2-15), two to twenty (2-20), two to twenty-five (2-25), two to thirty (2-30), two to thirty-five (2-35), two to forty (2-40), two to forty-five (2-45), two to fifty (2-50), two to fifty-five (2-55), two to sixty (2-60), two to sixty-five (2-65), two to seventy (2-70), two to seventy-five (2-75), two to eighty (2-80), two to eighty-five (2-85), two to ninety (2-90), two to ninety-five (2-95), two to one hundred (2-100), two to one hundred and'tvrenty (2-120), two to one hundred and twenty-five (2-125), two to one hundred and thirty (2-130), two to one hundred and forty (2-140), two to one hundred and fifty (2-150), two to one hundred and fifty-eight (2-158), five to ten (5-10), five to fifteen (5-15), five to twenty (5-20), five to, twenty-five (5-25), five to thirty (5-30), five to thirty-five (5-35), five to forty (5-40), five to forty-five (5-45), five to fifty (5-50), five to fifty-five (5-55), five to sixty (5-60), five to sixty-five (5-65), five to seventy (5-70), five to seventy-five (5-75), five to eighty (5-80), five to eighty-five (5-85), five to ninety (5-90), five to ninety-five (5-95), five to one hundred (5-100), five to one hundred and twenty (5-120), five to one hundred and twenty-five (5-125), five to one hundred and thirty (5-130), five to one hundred and forty (5-140), five to one hundred and fifty (5-150), five to one hundred and fifty-eight (5-158), ten to fifteen (10-15), ten to twenty (10-20), ten to twenty-five (10-25), and ten to thirty (10-30), ten to thirty-five (10-35), ten to forty (10-40), ten to forty-five (10-45), ten to fifty (10-50), ten to fifty-five (10-55), ten to sixty (10-60), ten to sixty-five (10-65), ten to seventy (10-70), ten to seventy-five (10-75), ten to eighty (10-80), ten to eighty-five (10-85), ten to ninety (10-90), ten to ninety-five (10-95), ten to one hundred (10-100), ten to one hundred and twenty (10-120), ten to one hundred and twertty-five (10-125), ten to one hundred and thirty (10-130), ten to one hundred and forty (10-140), ten to one hundred and fifty (10,150), ten to one hundred and fifty-eight (10-158), twenty to fifty (20-50), twenty to seventy-five (20-75), twenty to one hundred (20-100), twenty to one-hundred and twenty (20-120), twenty to one hundred and twenty-five (20-125), twenty to one hundred and thirty (20-130), twenty to one hundred and forty (20-140), twenty to one hundred and fifty (20-150), twenty to one.hundred and fifty-eight (20-158), fifty to seventy-five (50-75), fifty to one hundred (50-100), fifty to one hundred and twenty (50-120), fifty to one hundred and twenty-five (50-125), fifty to one hundred and thirty (50-130), fifty to one hundred and forty (50-140), fifty to one hundred and fifty (50-150), fifty to one hundred and fifty-eight (50-158), one hundred to one hundred and twenty-five (100-125), one hundred and twenty-five to one hundred and fifty (125-150), and one hundred and fifty to one hundred and fifty eight (150-158).

Diagnostic and Prognostic Methods The risk of developing Diabetes or Pre-diabetic condition can be detected by examining an "effective amount" of DBMARKER proteins, peptides, nucleic acids, polymorphisms, metabolites, and other analytes in a test sample (e.g., a subject denived sample) and comparing the effective amounts to*reference or index values. An "effective amount" can be the total amount or levels of DBMARKERS that are detected in a sample, or it can be a"normalized"
amount, e.g., the difference between DBMARKERS- detected in a sample and background noise.
Normalization methods and normalized values will differ depending on the method of detection.
Preferably, mathematical algorithms can be used to combine information from results of multiple individual DBMARKERS into a single measurement or index. Subjects identified as having an increased risk of Diabetes or a pre-diabetic condition can optionally be selected to receive treatment regimens, such as administration of prophylactic or therapeutic compounds such as "diabetes-modulating agents" as defined herein, or implementation of exercise regimens or dietary supplements to prevent or delay the onset of Diabetes or a pre-diabetic condition. A
sample isolated from the subject can comprise, for example, blood, plasma, blood cells, endothelial cells, tissue biopsies, lymphatic fluid, pancreatic juice, serum, bone marrow, ascites fluid, interstitial fluid (including, for example, gingival crevicular fluid), urine, sputum, saliva, tears, or other bodily fluids.
The amount of the DBMARKER protein, peptide, nucleic acid, polymorphism, metabolite, or other analyte can be measured in a test sample and compared to the normal control level. The term "normal control level", means the level of one or more DBIVIARKER proteins, nucleic acids, polymorphisms, metabolites, or other analytes, or DBM:ARKER
indices, typically found in a subject not suffering from Diabetes or a pre-diabetic condition and not likely to have Diabetes or a pre-diabetic condition, e.g., relative to samples collected from longitudinal studies of young subjects who were monitored until advanced age and were found not to develop Diabetes or a pre-diabetic condition. The "normal control level" can encompass values. obtained from a subject having "normal glucose levels" or "normoglycemic levels" as defined herein.
Altematively, the normal control level can mean the level of one or more DBMARKER protein, peptide, nucleic acid, polymorphism, metabolite, or other analyte typically found in a subject suffering from Diabetes or a pre-diabetic condition. The normal control level can be a range or an index. Alteznatively, the normal control level can be a database of pattems from previously tested subjects. A change in the level in the subject-derived sample of one or more DBMARKER protein, nucleic acid, polyinorphism, metabolite, or other analyte compared to the normal control level can indicate that the subject is suffering from or is at risk of developing Diabetes or a pre-diabetic condition. In contrast, when the methods are applied prophylactically, a similar level compared to the normal control level in the subject-derived sample of one or more DBMARKER proteins, nucleic acids, polymorphisms, metabolites, or other analytes can indicate that the subject is not suffering from, is not at risk or is at low risk of developing Diabetes-or a pre-diabetic condition.
. A reference value can refer to values obtained from a control subject or population whose diabetic state is known (i.e., has been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, or has not been diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition) or can be an index value or baseline value. The reference sample or index value or baseline value may be taken or derived from one or more subjects who have been exposed to the treatment, or may be taken or derived from one or more subjects who are at low risk of developing Diabetes or a pre-diabetic condition, or may be taken or derived from subjects who have shown improvements in Diabetes risk factors as a result of exposure to treatment. Altematively, the reference sample or index value or baseline value may be taken or derived from one or more subjects who have not been exposed to the treatment. For example, samples may be collected from subjects who have received initial treatment for Diabetes or a pre-diabetic condition and subsequent treatment for Diabetes or a pre-diabetic condition to monitor the progress of the treatment. A reference value can also comprise a value derived from risk prediction algorithms or computed indices from population studies such as those disclosed herein. A reference value can also be a value derived from a subject previously identified as having one or more complications related to type 2 Diabetes or a pre-diabetic condition, or altematively, a value derived from a subject who has not developed complications, or has not been previously diagnosed with or identified as having complications relating to type 2 Diabetes or a pre-diabetic condition. A reference value can also comprise a value corresponding to the normal control level or derived from one or more subjects having "normal glucose levels" as defined herein.
Differences in the level or amounts (which can be an "effective amount") of DBMARKERS measured by the methods of the present invention can comprise increases or decreases in the level or amounts of DBMARKERS. The increase or decrease in the amounts of DBMARKI RS relative to a reference value can be indicative of progression of.type 2 Diabetes or a pre-diabetic=condition, delay, progressioii, development, or amelioration of complications related to type 2 Diabetes or a pre-diabetic condition, an increase or decrease in the risk of developing type 2 Diabetes or a pre-diabetic condition, or complications relating thereto. The increase or decrease can be indicative of the success of one or more treatment regimens for type 2 Diabetes or a pre-diabetic condition, or can indicate improvements or regression of Diabetes risk factors. = The increase or decrease can be, for example, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%
of the reference value or normal control level. =
The difference in the level (or amounts) of DBACARKERS is preferably statistically significant. By "statistically significant", it is meant that the alteration is greater than what might be expected to happen by chance alone. Statistical significance can be determined by any method known in the art. For example, statistical significance can be determined byp-value.
The p-value is a measure of probability that a difference between groups during an experiment happened by chance. (P(z>zobserved)). For example, ap-value of 0.01 means that there is a 1 in 100 chance the result occurred by chance. The lower thep-value, the more likely it is that the difference between groups was caused by treatment. An alteration is statistically significant if the p-value is at least 0.05. Preferably, thep-value is 0.04, 0.03, 0.02, 0.01, 0.005, 0.001 or less.
As noted below, and without any limitation of the invention, achieving statistical significance generally but not always requires that combinations of several DBMARKERS be used together in panels and combined with mathematical algorithms in order to achieve a statistically significant DBMARKER index.
The "diagnostic accuracy" of a test, assay, or method concerns the ability of the test, assay, or method to distinguish between subjects having Diabetes or a pre-diabetic condition, or at risk for Diabetes or a pre-diabetic condition is based on whether the subjects have a "clinically significant presence" or a "clinically significant alteration" in the levels of one or more DBMARKERS. By "clinically signifcant presence" or "clinically significant alteration", it is meant that the presence of the DBMARKER (e.g., mass, such as milligrams, nanograms, or mass per volume, such as milligrams per deciliter or copy number of a transcript per unit volume) or an alteration in.the presence of the DBMARKER in the subject (typically in a sample from the subject) is higher than the predetermined cut-off point (or threshold value) for that DBMARKER
and therefore indicates that the subject has Diabetes or a pre-diabetic condition for which the sufficiently high presence of that protein, peptide, nucleic acid, polymorphism, metabolite or analyte is a marker.
The present inventioix may be used to make categorical or continuous measurements of the risk of conversion to Type 2 Diabetes, thus diagnosing a category of subjects defined as pre-Diabetic.
In the categorical scenario, the methods of the present invention can be used to discriminate between normal and pre-diabetic condition subject cohorts. In this categorical use of the invention, the terms "high degree of diagnostic accuracy" and "very high degree of diagnostic accuracy" refer to the test or assay for that DBMARKER (or DBMARKER
index;
wherein DBMARKER value encompasses any individual measurement whether from a single DBMARKER or derived from an index of DBMARKERS) with the predetermined cut-off point correctly (accurately). indicating the presence or absence of a pre-diabetic condition. A perfect test would have perfect accuracy. Thus, for subjects who have a pre-diabetic condition, the test would indicate only positive test results and would not report any of those subjects as being "negative" (there would be no "false negatives"). In other words, the "sensitivity" of the test (the true positive rate) would be 100%. On the other hand, for subjects who did not have a pre-diabetic condition, the test would indicate only negative test results and would not report any of those subjects as being "positive" (there would be no "false positives"). In other words, the "specificity" (the true negative rate) would be 100%. See, e.g., O'Marcaigh AS, Jacobson RM, "Estimating The Predictive Value Of A Diagnostic Test, How To Prevent Misleading Or Confusing Results," Clin. Ped. 1993, 32(8): 485-491, which discusses specificity, sensitivity, and positive and negative predictive values of a test, e.g., a clinical diagnostic test. In other embodiments, the present invention may be used to discriminate a pre-diabetic condition from Diabetes, or Diabetes from Normal. Such use may require different subsets of DBMARKERS(out of the total DBMARKERS as disclosed in Table 1), mathematical algorithm, and/or cut-off point, but be subject. to the same aforementioned measurements of diagnostic accuracy for the intended use.
In the categorical diagnosis of a disease, changing the cut point or threshold value of a test (or assay) usually changes the sensitivity and specificity, but in a qualitatively inverse relationship. For example, if the cut point is lowered, more subjects in the population tested will typically have test results over the cut point or threshold value. Because subjects who have test results above the cut point are reported as having the disease, condition, or syndrome for which the test is conducted, lowering the cut point will cause more subjects to be reported as having positive results (e.g., that they have Diabetes or a pre-diabetic condition).
Thus, a higher proportion of those who have Diabetes or a pre-diabetic condition will be indicated by the test to have it. Accordingly, the sensitivity (true positive rate) of the test will be increased. However, 'at the same time, there will be more false positives because more people who do not have the disease, condition, or syndrome (e.g., people who are truly "negative") will be indicated by the test to have DBMARKER values above the cut point and therefore to be reported as positive (e.g., to have the disease, condition, or. syndrome) rather than being correctly indicated by the test to be negative. Accordingly, the specificity (true negative rate).of the test will be decreased.
Similarly, raising the cut point will tend to decrease the sensitivity and increase the specificity.
Therefore, in assessing the accuracy and usefulness of a proposed medical test, assay, or method for assessing a subject's condition, one should always take both sensitivity and specificity into account and be mindful of what the cut point is at which the sensitivity and specificity are being reported because sensitivity and specificity may vary significantly over the range of cut points.
There is, however, an indicator that allows representation of the sensitivity and specificity of a test, assay, or method over the entire range of test (or assay) cut points with just a single value. That indicator is derived from a Receiver Operating Characteristics ("ROC") curve for the test, assay, or method in question. See, e.g., Shultz, "Clinical Interpretation Of Laboratory Procedures," chapter 14 in Teitz, Fundamentals of Clinical Chemistry, Burtis and Ashwood (eds.), 4`hedition 1996, W.B. Saunders Company, pages 192-199; and Zweig et al., "ROC Curve Analysis: An Example Showing.The Relationships Among.Serum Lipid And Apolipoprotein Concentrations In Identifying Subjects With Coronory Artery Disease," Clin.
Chem., 1992, 38(8): 1425-1428.
An ROC curve is an x-y plot of sensitivity on the y-axis, on a scale of zero to one (e.g., 100%), against a value equal to one minus specificity on the x-axis, on a scale of zero to one (e.g., 100%). In other words, it is a plot of the true positive rate against the false positive rate for that test, assay, or method. To construct the ROC curve for the test, assay, or method in question, subjects can be assessed using a perfectly accurate or "gold standard" method that is independent of the test, assay, or method in question to determine whether the subjects are truly positive or negative for the disease, condition, or syndrome (for example, coronary angiography is a gold standard test for the presence of coronary atherosclerosis). The subjects can also be tested using the test, assay, or method in que'stion, and for varying cut points, the subjects are reported as being positive or negative according to the test, assay, or method. The sensitivity (true positive rate) and the value equal to one minus the spedificity (which value equals the false positive rate) are determined for each cut point, and each pair of x-y values is plotted as a single point on the x-y diagram. The "curve" connecting those points is the ROC curve.
The ROC curve is often used in order to determine the optimal single clinical cut-off or treatment threshold value where sensitivity and specificity are maximized;
such a situation -represents the point on the ROC curve which describes the upper left corner of the single largest rectangle which can be drawn under the curve.
The total area under the curve ("AUC") is the indicator that allows represerccation of the sensitivity and specificity of a test, assay, or method over the entire range of cut points witli just a single value. The rnaximum AUC is one (a perfect test) and the minimum area is one half (e.g.
the area where there is no discrimination of nonnal versus disease). The closer the AUC is to one, the better is the accuracy of the test. It =should be noted that implicit in all ROC and AUC is the definition of the disease and the post-test time horizon of interest.
By a "high degree of diagnostic accuracy", it is meant a test or assay in which.the AUC
(area under the ROC curve for the test or assay) is at least 0.70, desirably at least 0.75, more desirably at least 0.80, preferably at least 0.85, more preferably at least 0.90, and most preferably at least 0.95.
By a "very high degree of diagnostic accuracy", it is meant a test or assay in which the AUC (area under the ROC curve for the test or assay) is at least 0.80, desirably at least 0.85, more desirably at least 0.875, preferably at least 0.90, more preferably at least 0.925, and most preferably at least 0.95.
Alternatively, in low disease prevalence tested populations (defined as those with less than 1% rate of occurrences per annum), ROC and AUC can be misleading as to the clinical utility of a test, and absolute and relative risk ratios as defined elsewhere in this disclosure can be employed to deternune the degree of diagnostic accuracy. Populations of subjects to be tested can also be categorized into quartiles, where the top quartile (25% of the population) comprises the group of subjects with the highest relative risk for developing or suffering from Diabetes or a pre-diabetic condition and the bottom quartile comprising the group of subjects having the lowest relative risk for developing Diabetes or a pre-diabetic condition.
Generally, values derived from tests or assays having over 2.5 times the relative risk from top to bottom quartile in a low prevalence population are considered to have a"high degree of diagnostic accuracy," and those with five to seven times the relative risk for each quartile are considered to have a very high degree of diagnostic accuracy. Nonetheless, values derived from tests or assays having only 1.2 to 2.5 times the relative risk for each quartile remain clinically useful are widely used as risk factors for a disease; such is the case with insulin levels or blood glucose levels with respect to their prediction of future type 2 Diabetes.
The predictive value of any test depends on the-sensitivity and specificity of the test, and on the prevalence of the condition in the population being tested. This notion, based on Bayes' theorem, provides that the greater the likelihood that the' condition being screened for is present in a subject or in the population (pre-test probability), the greater the validity of a positive test--and the greater the likelihood that the result is a true positive. Thus, the problem with using a test in any population where there is a low likelihood of the condition being present is that a positive result has limited value (i.e., more likely to be a false positive).
Similarly, in populations at very high risk, a negative test result is more likely to be a false negative. By defining the degree of diagnostic accuracy, i.e., cut points on a ROC curve, defining an acceptable AUC value, and determining the acceptable ranges in relative concentration of what constitutes an effective amount of the DBMARKERS of the invention allows one of skill in the art to use the DBMARKERS to diagnose or identify subjects with a pre-detezmined level of predictability.
Alternative methods of determining diagnostic accuracy must be used with continuous measurements of risk, which are commonly used when a disease category or risk category (such as a pre-diabetic condition) has not yet been clearly defined by the relevant medical societies and practice of medicine.
"Risk" in the context of the present invention can mean "absolute" risk, which refers to that percentage probability that an event will occur over a specific time period. Absolute risk can be measured with reference to either actual observation post-measurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period. "Relative" risk refers to the ratio of absolute risks of a subject's risk compared either to low risk cohorts or average population risk, which can vary by how clinical risk factors are assessed. Odds ratios, the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/(1-p) where p is the probability of event and (1- p) is the probability of no event) to no-conversion: Alternative continuous measures which may be assessed'in the context of the present.invention include time to Diabetes conversion and therapeutic' Diabetes conversion risk reduction ratios.
For such continuous measures, measures of diagnostic accuracy for a calculated index are=
typically based on linear regression curve fits between the predicted continuous value and the actual observed values (or historical index calculated value) and utilize measures such as R
squared, p values and confidence intervals. It is not unusual for predicted values using such algorithms to be reported including a confidence interval (usually 90% or 95%
CI) based on a historical observed cohort's predictions,. as in the test for risk of future breast cancer recurrence commercialized by Genomic Health (Redwood City, Caiifornia).
The ultimate determinant and gold standard of true risk conversion to Diabetes is actual conversions within a sufficiently large population and observed over a particular length of time.
However, this is problematic, as it is necessarily a retrospective point of view, coming after any opportunity for preventive interventions. As a result, subjects suffering from or at.risk of developing Diabetes or a pre-diabetic condition are commonly diagnosed or identified by methods known in the art, and future risk is estimated based on historical experience and registry studies. Such methods include, but are not Iimited to, measurement of systolic and diastolic blood pressure, measurements of body mass index, in vitro determination of total cholesterol, LDL, HDL, insulin, and glucose levels from blood samples, oral glucose tolerance tests, stress tests, measurement of human serum C-reactive protein (hsCRP), electrocardiogram (ECG), c-peptide levels, anti-insulin antibodies, anti-beta cell-antibodies, and glycosylated hemoglobin (HbAIJ. Additionally, any of the aforementioned methods can be used separately or in combination to assess if a subject has shown an "improvement in Diabetes risk factors." Such improvements include, without limitation, a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, an increase in insulin levels, or combinations thereof.

The oral glucose tolerance test (OGTT) is principally used for diagnosis of Diabetes Mellitus or pre-diabetic conditions when blood glucose levels are equivocal, during pregnancy, or in epidemiological studies (Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1, World Health Organization, 1999). The OGTT should be administered in the morning after at least 3 days of unrestricted diet (greater than 150 g of carbohydrate daily) and usual physical activity. A reasonable (30-50 g) carbohydrate-containing meal should be consumed on the evening before the test: The test should be preceded by an ovemight fast of 8-14 hours, during which water may be consumed. After collection of the fasting blood sample, the subject should drink 75 g of anhydrous glucose or 82.5 g of glucose monohydrate in 250-300 -X 0 ml of water over the course of 5 minutes. For children, the test load should be 1.75 g of glucose per kg body weight up to a total of 75 g of glucose. Timing of the test is from the beginning of the drink. Blood samples must be collected 2 hou'rs after the test load. As previously noted, a diagnosis of impaired glucose tolerance (IGT) has been noted as being only 50%
sensitive, with a >10% false positive rate, for a 7.5 year conversion to Diabetes when used at the WHO cut-off 1:5 points. This is a significant problem for the clinical utility of the test, as even relatively high risk ethnic groups have only a 10% rate of conversion to Diabetes over such a period unless otherwise enriched by other risk factors; in an unselected general population, the rate of conversion over such periods is typically estimated at 5-6%, or less than 1 lo per annum.
Other methods of measuring glucose in blood include reductiometric methods known in 20 the art such as, but not limited to, the Somogyi-Nelson method, methods using hexokinase and glucose dehydrogenase, immobilized glucose oxidase electrodes, the o-toluidine method, the ferricyanide method and the neocuprine autoanalyzer method. Whole blood glucose values are usually about 15% lower than corresponding plasma values in patients with a normal hematocrit reading, and arterial values are generally about 7% higher than corresponding venous values.
25 Subjects taking insulin are frequently requested to build up a"glycemic profile" by self-measurement of blood glucose at specific times of the day. A"7-poin.t profile"
is useful, with samples taken before and 90 minutes after each meal, and just before going to bed.
A subject suffering from or at risk of developing Diabetes or a pre-diabetic condition may also be suffering from or at risk of developing cardiovascular disease, hypertension or obesity.
30 Type 2 Diabetes in particular and cardiovascular disease have many risk factors in common, and many of these risk factors are highly correlated with one another. The relationships among these risk factors may be attributable to a small number of physiological phenomena, perhaps even a single phenomenon. In addition to detecting levels of one or more DBMARKERS of the' invention, subjects suffering from or at risk of developing Diabetes, cardiovascular disease, hypertension or obesity.can be identified by methods known in the art. For example, Diabetes is frequently diagnosed by measuring fasting blood glucose levels or insulin.
Normal adult glucose levels are 60-126 mg/dl. Normal insulin levels are 7 mU/ml 3mU. Hypertension is diagnosed by a blood pressure consistently at or above 140/90. Risk of cardiovascular disease can also be _ diagaosed by measuring cholesterol levels. For example, .LDL cholesterol above 137 or total cholesterol above 200 is indicative of a heighteined risk of cardiovascular disease. Obesity4s.
diagnosed for example, by body mass index. Body mass index (BMI) is measured (kg/m2 (or=
lb/in2 X 704.5)). Alternatively, waist circumference (estimates fat distribution), waist-to-hip ratio (estimates fat distribution), skinfold thickness (if measured at several sites, estimates fat distribution), or bioirim.pedance (based on principle that lean mass conducts current better than fat mass (i.e. fat mass impedes current), estimates % fat) can be measured. The parameters' for..
normal, overweight, or obese individuals is as follows: Underweight: BMI <1 8.5; Normal: 13MI
18.5 to 24.9; Overweight: BMI = 25 to 29.9. Overweight individuals are characterized as having a waist circumference of >94 cm for men or >80 cm for women and waist to hip ratios of > 0.95 in men and > 0.80 in women. Obese individuals are characterized as having a BMI of 30 to:34.9, being greater than 20% above "normal" weight for height, having a body fat percentage > 30%
for women and 25% for men, and having a waist circumference >102 cm (40 inches) for men or ~ 88 cm (35 inches) for women. Individuals with severe or morbid obesity are char'acterized as having a BMI of> 35_ Because of the interrelationship between Diabetes and cardiovascular disease, some or all of the individual DBMARKERS and DBMARKER expression profiles of the present invention may overlap or be encompassed by biomarkers of cardiovascular disease, and indeed may be useful in the diagnosis of the risk of cardiovascular disease.
Risk prediction for Diabetes Mellitus or a pre-diabetic condition can also encompass risk prediction algorithms and computed indices that assess and estimate a subject's absolute risk for developing Diabetes or a pre-diabetic condition with reference to a historical cohort. Risk assessment using such predictive mathematical algorithms and computed indices has =
increasingly been incorporated into guidelines for diagnostic testing and treatment, and encompass indices obtained from and validated with, inter alia, multi-stage, stratified samples from a representative population. A plurality of conventional Diabetes risk factors are incorpoiated into predictive models. A notable example of such algorithms include the Framingham.Heart Study (Kannel, W.B., et al, (1976) Am. J. Cardiol. 38: 46-51) and modifications of the Framingham Study, such as the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), also know as NCEP/ATP III, which incorporates a patient's age, total cholesterol concentration, HDL cholesterol concentration, smoking status, and systolic blood pressure to estimate a person's 10-year risk of developing cardiovascular disease, which is conunonly found- in subjects=suffering from or at risk for developing Diabetes Mellitus, or a pre-diabetic condition. The Framingham algorithm has been found to be modestly predictive of the :.' risk for develQping Diabetes Mellitus, or a pre-diabetic condition.
Other Diabetes risk prediction algorithms include, without limitation, the San Antonio Heart Study (Stern, M.P. et al, (1984) Am. J. Epidemiol. 120: 834-851; Stem, M.P. et al, (1993) Diabetes 42: 706-714; Burke, J.P. et al, (1999) Arch. Intern. Med. 159: 1450-1456), Archimedes (Eddy, D.M..and Schlessinger, L. (2003) Diabetes Care 26(11): 3.093-3101;
Eddy, D.M. and Schlessinger, L. (2003) Diabetes Care 26(11): 3102-3110), the Finnish-based Diabetes Risk Score (Lindstrom, J. and Tuomilehto, J. (2003) Diabetes Care 26(3): 725-731), and the Ely Study (Griffin, S.J. et al, (2000) Diabetes Metab. Res. Rev. 16: 164-171), the contents of which are expressly incorporated.herein by reference.
Archimedes is a mathematical model of Diabetes that simulates the disease state person-by-person, object-by-object and comprises biological=details that are continuous in reality, such as the pertinent organ systems, more than 50 continuously interacting biological variables, and the major symptoms, tests, treatments, and outcomes commonly associated with Diabetes.
Archimedes includes many diseases simultaneously and interactively in a single integrated physiology, enabling it to address features such as co-morbidities, syndromes, treatments and other multiple effects. The Archimedes model includes Diabetes and its complications, such as coronary artery disease, congestive heart failure, and asthma. The model is written in differential equations, using object-oriented programming and a construct called "features". The model comprises the anatomy of a subject (all simulated subjects have organs, such as hearts, livers, pancreases, gastrointestinal tracts, fat, muscles, kidneys, eyes, limbs, circulatory systems, brains, skin, and peripheral nervous systems), the "features" that determine the course of the disease and representing real physical phenomena (e.g., the number of milligrams of glucose in a deciliter of plasma, behavioral phenomena, or conceptual phenomena (e.g., the `progression" of disease), risk factors, incidence, and progression of the disease, glucose metabolism, signs and tests, diagnosis, symptoms, health outcomes of glucose metabolism, treatments, complications, deaths from Diabetes and its complications, deaths from other causes, care processes, and medical system resources. For a typical application of the model, there are thousands of simulated subjects, each with a simulated anatomy and physiology, who will get simulated diseases, can seek care at simulated health care facilities, will be seen by simulated health care personnel in simulated facilities, will be given simulated tests and treatments, and will have simulated outcomes. As in reality, each of the siniulated patients is different, with different characteristics, physiologies,. behaviors, and responses to treatments, all designed to match the individual variations seen in reality.
= The model is built by development of a=non-quantitative or conceptual description of the pertinent biology and pathology - the variables and relationships - as best they are understood with current information. Studies are then identified that pertain to the variables and relationships, and typically comprise basic research, epidemiological, and clinical studies that experts in the field identify as the foundations of their own understanding of the disease. That information is used to develop differential equations that relate the variables. The development of any particular equation in the Archimedes model involves finding the form and coefficients that best fit the available information about the variables, after which the equations are programmed into an object-oriented language. This is followed by a series of exercises in which the parts of the model are tested and debugged, first one at a time, and then in appropriate combinations, using inputs that have known outputs. The entire model can then be used to simulate a complex trial, which demonstrates not only the individual parts of the model, but also the connections between all the parts. The Archimedes calculations are performed using distributed computing techniques. Archimedes has been validated as a realistic representation of the anatomy, pathophysiology, treatrnents and outcomes pertinent to Diabetes and its complications (Eddy, D.M. and Schlessinger, L. (2003) Diabetes Care 26(11) 3102-3110).
The Finland-based Diabetes Risk Score is designed as a screening tool for identifying high-risk.subjects in the population and for increasing awareness of the modifiable risk factors and healthy lifestyle. The Diabetes Risk Score was deternzined from a random population sample of 35- to 64-year old Finnish men and women with no anti-diabetic drug treatment at baseline, and followed for 10 years. Multivariate logistic regression model coefficients were used to assign each variable category a score. The Diabetes Risk Score comprises the sum of these individual scores and validated in an independent population survey performed in 1992 with a prospective follow-up for 5 years. Age, BMI, waist circumference, history of anti-hypertensive drug treatment and high blood glucose, physical activity, and daily consumption of fruits, berries, or vegetables were selected as categorical variables.
The Finland-based Diabetes Risk Score values are derived from the coefficients of the logistic model by classifying them into five categories. The estimated probability (p) of drug-treated Diabetes over a 10-year span of time for any combination of risk factors can be calculated from the followirig coefficients:

e((30+Pixl+p2x2+'==) P(Diabetes) = ----------------------------1 + e(a0+plxt +0 2x2+ ) where (3o is the intercept and (31a P2, and so on represent the regression coefficients of the various categories of the risk factors xl, x2, and so on.
The sensitivity relates to the probability that the test is positive for subjects who will get drug-treated Diabetes in the future and the specificity reflects the probability that the test is negative for subjects without drug-treated Diabetes. The sensitivity and the specificity with 95%
confidence interval (CI) were calculated for each Diabetes Risk Score level in differentiating the subjects' who developed drug-treated Diabetes from those who did not. ROC
curves vvere plotted -for the Diabetes Risk score, the sensitivity was plotted on the y-axis and the false-positive rate (1-specificity) was plotted on the x-axis. The more accurately discriminatory the test, the steeper the upward portion of the ROC curve, and the higher the AUC, the optimal cut point being the peak of the curve. =
Statistically significant independent predictors of future drug-treated Diabetes in the Diabetes Risk Score are age, BMI, waist circumference, antihypertensive drug therapy, and history of high blood glucose levels. The Diabetes Risk Score model comprises a concise model that includes only these statistically significant variables and a full model, which includes physical activity and fruit and'vegetable consumption.
The San Antonio Heart Study is a long-term, connnunity-based prospective observational study of Diabetes and cardiovascular disease in Mexican Americans and non-Hispanic Caucasians. The study initially enrolled 3,301 Mexican-American and 1,857 non-Hispanic Caucasian men and non-pregnant women in two phases between 1979 and 1988.
Participants were 25-64 years of age at enrollment and were randomly selected from low, middle, and high-income neighborhoods in San Antonio, Texas. A 7-8 year follow-up exam followed approximately 73% of the surviving individuals initially enrolled in the study. Baseline characteristics such as medical history of Diabetes, age, sex, ethnicity, BMI, systolic and diastolic blood pressure, fasting and 2-hour plasma glucose levels, fasting serum total cholesterol, LDL, and HDL cholesterol levels, as well as triglyceride levels, were compiled and assessed. A
multiple logistic regression model with incident Diabetes as the dependent variable and the aforementioned baseline characteristics were applied as independent.variables.
Using this model, univariate odds ratios can be computed for each potetitial risk factor for men and women *
separately and for both sexes combined. , For continuous risk factors, the odds ratios can be presented for a 1-SD increment. A multivari ate predicting model with both sexes combined can be developed using a stepwise logistic regression procedure in which the variables that had shown statistically significarit odds ratios when examined individually were allowed to enter the model. This multivariable model is then analyzed by ROC curves and 95% CIs of the areas under the ROC curves estimated by non-parametrie algorithms such as those described by DeLong (DeLong E.R. et al, (1988) Biometrics 44: 837-45). The results of the'San Antonio Heart Study indicate that pre-diabetic subjects have an atherogenic pattem of risk factors (possibly caused by obesity, hyperglycemia, and especially hyperinsulinemia), which may be present for many years and may contribute to the :nsk of macrovascular disease as much as the duration of clinical Diabetes itself.
Despite the numerous studies and algorithms that have been used to assess the risk of Diabetes or a pre-diabetic condition, the evidence-based, multiple risk factor assessment approach is only moderately accurate for the prediction of short- and long-term risk of manifesting Diabetes or a pre-diabetic condition in individual asymptomatic or otherwise healthy subjects. Such risk prediction algorithms can be advantageously used in combination with the DBNs1ARKERS of the present invention to distinguish between subjects in a population of interest to determine the risk stratification of developing Diabetes or a pre-diabetic condition.
The DBMARKERS and methods of use disclosed herein provide tools that can be used in combination with such risk prediction algorithms to assess, identify, or diagnose subjects who are asymptomatic and do not exhibit the conventional risk factors. =
The data derived from risk prediction algorithms and from the methods of the present invention can be compared by linear regression. Linear regression analysis models the relationship between two variables by fitting a linear equation to observed data. One variable is considered to be an explanatory variable, and the other is considered to be a dependent variable.

For example, values obtained from the Archimedes or San Antonio Heart analysis can be used as a dependent variable and analyzed against levels of one or more DBMARKERS as the explanatory variables in an effort to more fully define the underlying biology implicit in the calculated algorithm score (see Examples). Alternatively, such risk prediction algorithms, or their individual inputs, which are generally DBMARKERS themselves, can be directly ' incorporated into the practice of the present invention, with the combined algorithm compared against actual observed results'in a historical cohort.
A linear regression line has an equation of the form Y = a + bX, where X is the explanatory variable and Y is the dependent variable. The slope of the line is b, and a is the intercept (the value of y when x = 0). A numerical measure of association between two variables is the "correlation coefficient,"or R, which is a value between -1 and I
indicating the strength of the'association of the observed data for the two variables. This is also often reported as the square of the correlation coefficient, as the "coefficient, of. determination"
or Rz; in this form it is the proportion of the total variation in Y explained by fi:tting the line. The most connnon method for fitting a regression line is the method of least-squares. Tlus method calculates the best-fitting line for the observed data by minimizing the sum of the squares of the vertical deviations from each data-pciint to the line (if a point lies on the fitted line exactly, then its vertical deviation is 0).
Because the deviations are first squared, then summed, there are no cancellations between positive and negative values.
After a regression line has been computed for a group of data, a point which lies far from the line (and thus has a large residual value) is known as an outlier. Such points may represent erroneous data, or may indicate a poorly fitting regression line. If a point lies far from the other data in the horizontal direction, it is known as an influential observation.
The reason for this distinction is that these points have rnay have a significant impact on the slope of the regression line. Once a regression model has been fit to a group of data, examination of the residuals (the deviations from the fitted line to the observed values) allows one of skill in the art to investigate the validity of the assumption that a linear relationship exists. Plotting the residuals on the y-axis against the explanatory variable on the x-axis reveals any possible non-linear relationship among the variables, or might alert the skilled artisan to investigate "lurking variables." A "lurking variable" exists when the relationship between two variables is significantly affected by the presence of a third variable which has not been included in the modeling effort.

Linear regression analyses can be used, inter alia, to predict.the risk o developing Diabetes or a pre-diabetic condition based upon correlating the levels of one or more DBMARKERS in a sample from a subject to that subjects' actual observed clinical outcomes, or in combination with, for example, calculated Archimedes risk scores, San Antonio Heart risk scores, or other known methods of diagnosing or predicting the prevalence of Diabetes or a pre=
diabetic condition. Of particular use, however, are non-linear equations and analyses to deternzine the relationship between known predictive models of Diabetes and levels of DBMARKERS detected in a subject sample. Of particular interest are structural and synactic classification -algorithms, and methods of risk index construction; utilizing pattern recognition-features, including established techniques such as the Kth-Nearest Neighbor, Boosting, Decision Trees, Neural -Networks, Bayesian Networks, Support Vector Machines, and Hidden Markov Models. Most commonly used are classification algorithms using logistic regression, which are the basis for the Framingham, Finnish, and San Antonio Hearfrisk. scores.
Furthermore, the.
application o.f.such techniques to panels of multiple DBMA.RKERS is encompassed by or within the ambit of the present invention, as is the use of such combination to create single numerical "risk indices"-or "risk scores" encompassing information from multiple DBMARKER inputs.
Factor'analysis is a mathematical technique by which a large number of correlated variables (such as Diabetes risk factors) can be reduced to fewer "factors"
that represent distinct attributes that account for a large proportion of the variance -in the original variables (Hanson, R.L. et al, (2002) Diabetes 51: 3120-3127). Thus, factor analysis is well suited for identifying components of Diabetes Mellitus and pre-diabetic conditions such as IGT, IFG, and Metabolic Syndrome. Epiderniological studies of factor "scores" from these analyses can further determine relations between components of the metabolic syndrome and incidence of Diabetes. The premise underlying factor analysis is that correlations observed among a set of variables can be explained by a small number of unique unxneasured variables, or "factors".
Factor analysis involves two procedures: 1) factor extraction to estimate the number of factors, and 2) factor rotation to determine constituents of each factor in terms of the original variables.
Factor extraction can be conducted by the.method of principal components.
These components are linear combinations of the original variables that are constructed so that each component has a correlation of zero with each of the other components. Each principal component is associated with an "eigen-value," which represents the variance in the original variables explained by that component (with each original variable standardized to have a variance of I.). The number of principal components that can be constructed is equal to the number of original variables. In factor analysis, the number of factors is customarily determined by retention of only those components that account for more of the total variance than any single original variable (i.e., those components with eigen-values of>1).
Once the number of factors has been established, then factor rotation is conducted to determine the composition of factors that has the most parsimonious interpretation in terms of the original variables. In factor rotation, "faotor loadings," which represent correlations of each =-factor with the original variables, are changed so that these factor loadings are made as close to 0 or 1 as possible (with the constraint that the total amount of variance explained by the factors ' remains unchanged). A number of methods for factor rotation have been developed and can be distinguished by whether they require the fmal set of factors to remain uncorrelated with one another (also known as "orthogonal methods") or by whether they allow factors to be correlated ("oblique methods"). In interpretation of.fxctor analysis, the pattern of factor loadings is examined to determine which original variables represent primary constituents of each factor.
15. Coiiventionaily, variables that have a factor loading of >0.4 (or less than -0.4) with a particular factor are considered to be its major constituents. Factor analysis can be very useful in constructing DBMARKER panels from their constituent components, and in grouping substitutable groups of markers.
Comparison can be performed on test ("subject") and reference ("control") samples measured concurrently or at temporally distinct times. An example of the latter is the use of compiled expression information, e.g., a sequence database, which assembles information about expression levels of DBMARKERS. If the reference sample, e.g., a control sample is from a subject that does not have Diabetes a similarity in the amount of the DBMARKERS in the subject test sample and the control reference sample indicates that the treatment is efficacious.
However, a change in the amount of one or more DBMARKERS in the test sample and the reference sample can reflect a less favorable clinical outcome or prognosis.
"Efficacious" or "effective" means that the treatment leads to an decrease or increase in the amount of one or more DBIVIA.RKERS, or decrease of serum insulin levels or blood glucose levels in a subject.
Assessment of serum insulin or blood glucose levels can be analyzed using standard clinical protocols. Efficacy can be determined in association with any known method for diagnosing or treating Diabetes.

Levels of an effective amount of DBMARKER proteins, peptides, nucleic acids, polymorphisms, metabolites, or other analytes also allows for the course of treatment of Diabetes or a pre-diabetic condition to be monitored. In this method, a biological sample can be provided from a subject undergoing treatment regimens, e.g., drug treatments, for Diabetes. 'Such treatment regimens can include, but are not limited to, exercise regimens, dietary supplementation (including without limitation, alpha-lipoic acid, chromium, coenzyme Q 10, garlic., inagnesium, and omega-3 fatty acids), surgical intervention (such as but not limited to gastric bypass, angioplasty, etc.), and treatment with therapeutics or prophylactics used-in ..
subjects diagnosed or identified with Diabetes or a pre-diabetic condition, such as for example, diabetes-modulating agents as defined herein. If desired, biological samples are obtained from the subject at various time points before, during, or after treatmeint. Levels of an effective amount of DBMARKER proteins, peptides, nucleic acids, polymorphisms, metabolites, or other analytes can then be determined and compared to a'reference value, e.g. a control subject or.
population whose diabetic state is known or an index value or baseline value.
The reference sample or index value or baseline value may be taken or derived from one or more subjects who have been exposed to the treatment, or may be taken or derived from one or more subjects who are at low risk of developing Diabetes or a pre-diabetic condition, or may be taken or derived from subjects who have shown improvements in Diabetes risk factors as a result of exposure to treatment. Alternatively, the reference sample or index value or baseline value may be taken or 20'= derived from one or more subjects who have not been exposed to the treatment. For example, samples may be collected from subjects who have received initial treatment for Diabetes or a pre-diabetic condition and subsequent treatment for Diabetes or a pre-diabetic condition to monitor the progress of the treatment. A reference value can also comprise a value derived from risk prediction algorithms or computed indices from population studies such as those disclosed herein.
The DBMARKERS of the present invention can thus be used to generate a "reference expression profile" which comprises a pattern of expression levels of DBMARKERS detected in those subjects who do not have Diabetes or a pre-diabetic condition such as impaired glucose tolerance, and would not be expected to develop Diabetes or a pre-diabetic condition. The DBMARKERS disclosed herein can also be used to generate a "subject expression profile"
comprising a pattern of expression levels of DBMARKERS taken from subjects who have Diabetes or a pre-diabetic condition like impaired glucose tolerance. The subject expression profiles can be compared to a reference expression profile to diagnose or identify subjects at risk for developing Diabetes or a pre-diabetic condition, to monitor the progression of disease, as well as the rate of progression of disease, including development or risk of development of complications related to type 2 Diabetes or pre-diabetic conditions, and to monitor the effectiveness of Diabetes or pre-diabetic condition treatment modalities. The reference and subject expression profiles of the present invention can be contained in a machine-readable medium, such as but not limited to, analog tapes or digital xnedia like those readable by a VCR, CD-ROM, DVD-ROM, USB flash media, among others. Such machine-readable media can also contain additional test results, such as, -without linnitation, measurements of conventional Diabetes risk factors like systolic and diastolic blood pressure, blood glucose levels, insulin levels, BMI indices, and cholesterol (LDL and HDL) levels. Altematively or additionally, the machine-readable media can also comprise subject information such as medical history and any relevant family history. The machine-readable media can also *contain information relating to other Diabetes-risk algorithms and computed indices such as those described herein.
Differences in the genetic makeup of subjects can result in differences in their relative abilities to metabolize various agents, which may modulate the symptoms or risk factors of Diabetes or a pre-..eiiabetic condition. Subjects that have Diabetes or a pre-diabetic condition, or at risk for developing Diabetes or a pre-diabetic condition can vary in age, ethnicity, body mass index (BMI), total cholesterol levels, blood glucose levels, blood pressure, LDL atnd HDL levels, and other parameters. Accordingly, use of the DBIVIA.RKERS disclosed herein allow for a pre-determined level of predictability that a putative therapeutic or=prophylactic to be tested in a selected subject will be suitable for treating or preventing Diabetes, a pre-diabetic condition, or complications thereof in the subject.
To identify therapeutics or agents that are appropriate for a specific subject, a test sample from the subject can be exposed to a therapeutic agent or a drug, and the level of one or more of DBMARKER proteins, nucleic acids, polymorphisms, metabolites or other analytes can be determined. The level of one or more DBMARKERS can be compared to a sample derived from the subject at a first period of time before and at a second period of time after treatment or exposure to a therapeutic agent or a drug, or can be compared to samples derived from one or more subjects who have shown improvements in Diabetes or pre-diabetic condition risk factors as a result of such treatment or exposure. Examples of such therapeutics or agents frequently used in Diabetes treatments, and may modulate the symptoms or risk factors of Diabetes include, b.ut are not limited to, sulfonylureas like glimepiride, glyburide (also known in the art as glibenclamide), glipizide, gliclazide; biguanides such as metformin; insulin (including inhaled formulations such as Exubera), and insulin analogs such as insulin lispro (Humalog), insulin glargine (Lantus), insulin detemir, and insulin glulisine; peroxisome proliferator-activated receptor-y (PPAR-y) agonists such as the thiazolidinediones including troglitazone (Rezulin), pioglitazone (Actos), rosiglitazone (Avandia), and isaglitzone (also known as netoglitazone);
dual-acting PPAR agonists such as BMS-298585 and tesaglitazar; insulin secretagogues including metglitinides such as repaglinide and nateglinide; analogs of glucagon-like peptide-1 (GLP-1) such as exenatide (AC-2993) and liraglutide (insulinotropin);
inhibitors of dipeptidyl peptidase IV like LAF-237; pancreatic lipase inhibitors such as orlistat; a-glucosidase inhibitors such as* acarbose; miglitol, and voglibose; and combinations. thereof, particularly metformin and glyburide (Glucovance), metformin and rosiglitazone (Avandamet), and metformin and glipizide (Metaglip). Such=therapeutics or agents have been prescribed for subjects diagnosed with Diabetes or a pre-diabetic condition, and may modulate tfie symptoms or risk factors of Diabetes or a pre-diabetic condition (herein, `diabetes-modulating agents").
A subject sample can be incubated in the presence of a candidate agent and the pattern of DBMARKER expression in the test sample is measured and compared to a reference profile, e.g., a Diabetes reference expression profile or a non-Diabetes reference expression profile or an index value or baseline value. The test agent can be any compound or composition or combination thered"f. For example, the test agents are agents frequently used in Diabetes treatment regimens and are described herein.
Table 1 comprises the one hundred and fifty-eight (158) DBMARKERS of the present invention. One skilled in the art will recognize that the DBMARKERS presented herein encompasses all forms and variants, including but not limited to, polymorphisms, isoforms, mutants, derivatives, precursors including nucleic acids, receptors (including soluble and transmembrane receptors), ligands, and post-translationally modified variants, as well as any multi-unit nucleic acid, protein, and glycoprotein structures comprised of any of the DBMARKERS as constituent subunits of the fully assembled structure.

Table 1: DBMARKERS
DBMARKER Common Name Alternative Name I Serpina 3M C-terminal fragment of a predicted protein, similar to serine protease inhibitor 2.4 2 S in2a 3 Fetuin beta Fetub; Fetuin (3; Fetuin B
4 Apolipoprotein C-Ill Apoc3 precursor Predicted protein, similar to Apoc2, predicted A oli o rotein C2 6 Alpha-2-HS-glycoprotein = a-2-HS-glycoprotein; =Ahsg; Fetuin a; Fetuin A;
Aa2-066 7 T-]cininogen II precursor 8 Alpha-l-macroglobulin a-l-macroglobulin; A2MG; Pzp;.pregnancy-zone protein 9 Serpin Cl Serine/cysteine proteinase inhibitor, clade C, member I ( redicted) Coagulation factor 2 = F2..
11 Inter-alpha-inhibitor H4 ITIH4 heavy chain 12 Vitamin D binding protein Gc; VTDB
r e tide 13 Low-molecular weight T- Kininogen; LMW T-kininogen I precursor; major kininogen I recursor acute phase al ha-1 protein precursor 14 Apoli o rotein A-1 Prea oli o rotein A-1; ApoAl Predicted protein, similar to Apoc2 apolipoprotein C-II
precursor 16 Thrombin Prothrombin pTdcursor; THRB
17 A oli o roteinE A oE
18 Liver regeneration-related Tf rotein LRRG03 19 Apoli o rotein A-IV ApoA4 Alpha-I -inhibitor 3 LOC297568 precursor 22 Histidine-rich gl co rotein Hrg 24 Complement component C9 C9 recursor A oli o rotein H ApoH
26 B-factor, properdin Cfb 27 Hemopexin Hpx 28 Calnexin Ca(2+)-binding hos ho rotein p90 29 Reg3a Rn. 11222; regenerating islet-derived 3 alpha LOC680945 Rn.1414; similar to stromal cell-derived factor 2-like 1 31 Pap Rn.9727; pancreatitis-associated protein 32 Ptfl a Rn.10536; Pancreas specific transcription factor, la 33 Matl a Rn.10418; methionine adenosyltransferase I, al ha 34 Nu rl Rn.l 1182; nuclear rotein 1 Rn.128013 36 Chacl (predicted) Rn.23367; ChaC; cation transport regulator-like 1 DBMARKER Common Name Alternative Name 37 Slc7a3 Rn.9804; solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 38 LOC312273 Rn.13006; trypsin V-A
39 Rn.47821 40 Ptger3 Rn.10361; prostaglandin E receptor 3 (subtype 41 RGD 1562451 Rn.199400; similar to Pabpc4 predicted protein 42 RGD 1566242 Rn.24858; similar to RIKEN cDNA 1500009M05 43 Cyp2d26 Rn.91355; Cytochrome P450, family 2, subfamily d, polypeptide 26 44 Rn. 17900 Similar to aldehyde dehydrogenase 1 family, member L2 45 LOC286960 Rn.10387; reprotrypsinogen IV
46 Gls2 Rn.10202; glutaminase 2 (liver, mitochondrial) 47 Nme2 Rn.927; expressed in non-metastatic cells 2 48 Rn.165714 49 P2rx1 Rn.91176; purinergic receptor PX2, ligand-gated ion channel, I
50 Pdk4 Rn.30070; pyruvate dehydrogenase kinase, isoenzyme 4 51 Amyl Rn.116361; amylase 1, salivary 52 Cbs Rn.87853; cystathionine beta synthase 53 Mtel Rn.37524; mitochondrial acyl-CoA thioesterase I
54 Spinki Rn.9767; serine protease inhibitor, Kazal type 1 = 55 Gatm =Rn.1766 1; glycine amidinetransferase (L-arginine:glycine amidinotransferase) =56 Tmed6_predicted Rn.19837; transmembrane emp24 protein transport domain containing 6 57 Tff2 Rn.34367; trefoil factor 2(spasmolytic protein 1) 58 Hsdl7bl3 Rn.25104; hydroxysteroid (17-beta) dehydro enase 13 150 Rn.11766 Similar to LRRGT00012 61 Gnmt Rn. 11142; glycine N-methyltransferase 62 Pah Rn. 1652; phenylalanine h droxylase 63 Serpini2 Rn.54500; serine/cysteine proteinase inhibitor, ciade 1, member 2 64 RGD1309615 Rn.167687 65 LOC691307 Rn.79735; similar to leucine rich repeat containing 39 isoform 2 66 Eprs Rn.21240; glutamyl-prolyl-tRNA synthetase 67 Pck2_predicted Rn.35508; phosphoenolpyruvate carboxykinase 2 mitochondrial 68 Chd2_predicted Rn. 162437; chromodomain helicase DNA binding rotein 2 69 Rn.53085 70 Rn. l 2530 71 NIPK Rn.22325; tribbles homolog; cDNA clone RPCAG66 3' end, mRNA sequence 72 SIc30a2 . Rn.1 1135; solute carrier family 30 (zinc trans orter), member 2 73 SerpinalO Rn.10502; serine/cysteine peptidase inhibitor, clade A, member 10 74 Cfi Rn.7424; com lement factor I
75 Cckar Rn.10184;cholecystokinin A receptor DBMARKER Common Name Alternative Name 76 LOC689755 Rn.151728; LOC689755 77 BhlhbB Rn.9897; basic helix-loop-helix domain containing class B, 8 78 An e Rn.11132; alanyl (membrane) aminopeptidase) 79 Asns Rn.11172; asparagine syntbetase 80 S1c7a5 Rn.3226 1; solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 81 Us 3 redicted Rn. 12678; ubiguitin specific protease 43 82 Csnklal Rn.238I0; casein kinase 1, alpha I
83 Cml2 Rn.160578; camello-like 2 84 Pab c4 = Rn.199602 85 Gjb2 Rn.198991; gap junction membrane channel protein beta 2 86 N f Rn.1.1331;=inerve growth factor, gamma 87 Clca2 redicted ,Rn.48629 88 RGD1565381 Rn.16083; similar to RIKEN cDNA 181003M07 89 Qscn6 Rn.44920; uiescin Q6 90 CldnlOpredicted Rn.99994; claudin 10 91 Spink3 Rn.144683; serine protease inhibitor, Kazal type 3 92 LOC498174 ., Rn.163210; similar to NipSnap2 protein lioblastoma amplified sequence) 93 Rn.140163 Similar to methionine-tRNA synthetase 94 Cyr6I Rn.22129; cysteine rich protein 61 95 RGD1307736 Rn.162140; Similar to KIA.A0152 96 Ddit3 Rn.1 1183; DNA damage inducible transcript 97 Re 1 Rn.11332; regenerating islet derived I
98 Eif4b Rn.95954; eukaryotic translation initiation factor 99 Rnase4 Rn.I742; ribonuclease, RNase A family 4 .100 Cebpg Rn.10332; CCAAT/enhancer binding protein C/EBP , amma 1.01 siat7D Rn.195322; alpha-2,6-sialyltransferase ST6Ga1NAc IV
102 Herpudl Rn.4028; homocysteine-inducible, ubiquitin-like domain member I
103 Unknown rat cDNA
104 Gcat Rn.43940; glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase) 105 RGD1562860 Rn.75246; similar to RIKEN cDNA 2310045A20 106 Hs a9a redicted Rn.7535; heat shock 70 kD protein 9A
107 Dbt Rn.198610; dihydrolipoamide branched chain transacylase E2 108 Bspry Rn.53996; B-box and SPRY domain containing 109 Putl Rn.1 1382; fucosyltransferase I
110 Rp13 Rn.107726; ribosomal protein L3 111 Rn.22481 Similar to NP_083520.1 acylphosphatase 2, muscle type 112 Unknown rat cDNA
113 Vldlr Rn.9975; very low density li o rotein receptor 114 RGD1311937 Rn.33652; similar to MGC17299 115 RGD1563144 Rn.14702; Similar to EMeg32 protein 116 Rn.43268 117 pre-mtHSP70 Rn.7535; 70 kD heat shock protein precursor 118 Ddahl Rn.7398; dimethylarginine DBMARKER Common Name Alternative Name dimeth laminohydrolase 1 119 RAMP4 Rn.2119; ribosome associated membrane protein 4 120 Rn.169405 121 Ccbel_predicted Rn.199045; collagen and calcium binding EGF
domains I
122 Dnajc3 Rn.162234; DnaJ (Hsp40) homolog, subfamily C, member 3 123 Mtac2dl Rn.43919; membrane targeting (tandem )C2 domain containing 1 124 RGD1563461 Rn.199308 125 Gimap4 Rn.198155; GTPase, IMAP family member 4 126 S100b Rn.8937; S100 protein, beta ol e tide 127 Klf2_predicted Rn.92653; Kruppel-like factor 2 (lung) 128 RGD1309561 Rn.102005; similar to FLH31951 129 NAP22 Rn.163581 130 Sfrs3_predicted Rn.9002; splicing factor,;arginine/serine-rich 3 131 Rn.6731 132 Cd53 Rn.31988; CD53 antigen 133 RGD 1561419 Rn.131539; similar to RIKEN cDNA 6030405P05 gene 134 I12rg Rn.14508; interleukin=2 receptor, gamma 135 LOC361346 Rn.31250; simiiar to chromosome 18 open reading frame 54 136 Cd38 Rn:11414; CD38 antigen 137 Plac8 redicted Rn.2649; lacenta-s ecific 8 .138 LOC498335 Rn.6917; similar to small inducible cytokine B13 precursor (CXCL13) 139 Igfbp3 Rn.26369; insulin-like growth factor binding protein 3 140 Ptprc Rn.90166; protein tyrosine phosphatase, receptor type C
141 RTI-Aw2 Rn.40130; RTI class Ib, locus Aw2 142 Rac2 Rn.2863; RAS-related C3 botulinum substrate = 143 Rn.9461 144 Fos Rn.103750; FBJ murine osteosarcoma viral oncogene homolog 145 Arhgdib Rn.15842; Rho, GDP dissociation inhibitor (CDI) beta 146 Sgnel Rn.6173; secretory granule neuroendocrine protein 147 Lck_mapped Rn.22791; lymphocyte protein tyrosine kinase (mapped) 148 Fcgr2b Rn.33323; Fc receptor, IgG, low affinity Ilb 149 SIfn8 Rn.137139; Schlafen 8 150 Rab8b Rn.10995; RAB8B, member RAS oncogene family 151 Rn.4287 152 RGD1306939 Rn.95357; similar to mKIAA0386 protein 153 Tnfrsf26_predicted Rn.162508; tumor necrosis factor receptor superfamily, member 26 154 Ythdf2_predicted Rn.21737; YTH domain family 2 155 RGD1359202 Rn. 10956; similar to immunoglobulin heavy chain 6 (Igh-6) DBMARKER = Common Name Alternative Name 156 RGD1562855 Rn_117926; similar to I ka a chain 157 Igha mapped Rn.109625; imYnunoglobulin heavy chain (alpha ol e tide) (ma ed) 158 Cc121b Rn.39658; chemokine (C-C motit) ligand 21b (serine) Levels of the DBMARKERS can be determined at the protein or nucleic acid level using any method known in the art. DBMARKER amounts can be detected, inter alia, electrophoretically (such as by agarose gel electrophoresis, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Tris-HCl polyacrylamide gels, non-denaturing protein gels, two-dimensional gel electrophoresis (2DE), and the like), immunochernically (i.e., radioimmunoassay, immunoblotting, immunoprecipitation, immunofluorescence, enzyme-linked immunosorbent assay), by "proteomics technology", or by "genomic analysis."
For exainple; at the nucleic acid level, Northern and Southern hybridization analysis, as well as ribonuclease protection assays using probes which specifically recognize one or more of these sequences-can be used to determine gene expression. Alternatively, expression can be measured using reverse-transcription-based PCR assays (RT-PCR), e.g., using primers specific for the differeintially =
expressed sequence of genes. Expression can also be determined at the protein level, e.g., by measuring the levels of peptides encoded by the gene products described herein, or activities thereof. Such methods are well known in the art and include, e.g., immunoassays based on' antibodies to proteins encoded by the genes, aptamers or molecular imprints..
Any biological material can be used for the detection/quantification of the protein or its activity. Alternatively, a suitable method can be selected to determine the activity of proteins encoded by the marker genes according to the activity of each protein analyzed.
"Proteomics technology" includes, but is not limited to, surface enhanced laser desorption ionization (SELDI), matrix-assisted laser desorption ionization-time of flight (MALDI-TOF), high performance liquid chromatography (HPLC), liquid chromatography with or without mass spectrometry (LC/MS), tandem LC/MS, protein arrays, peptide arrays, and antibody arrays.
"Genome analysis" can comprise, for example, polymerase chain reaction (PCR), real-time PCR (such as by Light CyclerM, available from Roche Applied Sciences), serial analysis of gene expression (SAGE), Northern blot analysis, and Southern blot analysis.
Microarray technology can be used as a tool for analyzing gene or protein expression, comprising a small membrane or solid, support (such as but not limited to microscope glass slides, plastic supports, silicon chips or wafers with or without fiber optic detection means, and membranes including nitrocellulose, nylon, or polyvinylidene fluoride). The solid support can be chemically (such as silanes, streptavidin, and numerous other examples) or physically derivatized (for example, photolithography) to enable binding of the analyte of interest, usually nucleic acids, .proteins, or metabolites or fragments thereof. The nucleic acid or protein can be printed (i.e., inkjet printing), spotted, or synthesized in situ. Deposition of the nucleic acid or protein of interest can be achieved by xyz robotic niicroarrayers, which utilize automated-spotting devices with very precise movement controls on the x-, y-, and z-axes, in combination with pin technology to provide accurate, reproducible spots on the arrays. The analytes of interest are placed on the solid support in an orderly or fixed arrangement so as to facilitate easy identification of a particularly desired analyte. A number of microarray formats are comniercially available from, inter alia, Affymetrix, Arraylt, Agilent Technologies, Asper Biotech, BioMicro, CombiMatrix, GeiiePix, Nanogen, and Roche Diagnostics.
The nucleic acid or protein of interest can be synthesized in the presence of nucleotides or amino acids tagged with one or more detectable labels. Such labels include, for example, fluorescent=dyes and chemilununescent'labels_ In particular, for microarray detection, fluorescent dyes such as but not limited to rhodarnine, fluorescein, phycoerythrin, cyanine dyes like Cy3 and Cy5', and conjugates like streptavidin-phycoerythrin (when nucleic acids or proteins are tagged with biotin) are frequently used.
Detection of fluorescent signals and image acquisition are typically achieved using confocal fluorescence laser scanning or photomultiplier tube, which provide relative signal intensities and ratios of analyte abundance for the nucleic acids or proteins represented on the array. A wide variety of different scanning instnuments are available, and a number of image acquisition and quantification packages are associated with them, which allow for numerical evaluation of - -combined selection criteria to define optimal scanning conditions, such as median value, inter-quartile range (IQR), count of saturated spots, and linear regression between pair-wise scans (r2 and P). Reproducibility of the scans, as well as optimization of scanning conditions, background correction, and normalization, are assessed prior to data analysis.
Normalization refers to a collection of processes that are used to adjust data means or variances for effects resulting from systematic non-biological differences between arrays, subarrays (or print-tip groups), and dye-label channels. An array is defined as the entire set of target probes on the chip or solid support. A subarray or print-tip group refers to a subset of .
those target probes deposited by the same print-tip, which can be identified as distinct, smaller arrays of proves within the full array. The dye-label channel refers to the fluorescence frequency of the target sample hybridized to the chip. Experiments where two differently dye-labeled samples are mixed and hybridized to the same chip are referred to in the art as "dual-dye experiments", which result in a relative, rather than absolute, expression value for each target on the array, often represented as the log of the ratio between "red" channel and "green channel."
Normalization can be performed according to ratiometric or absolute value methods.
Ratiometric analyses are mainly employed in dual-dye experiments where one channel or array is considered in relation to a common reference. A ratio of expression for each target probe is calculated between test and reference sample, followed by a transformation of the ratio into log2(ratio) to symmetrically represent relative changes. Absolute value methods are used frequently in single-dye experiments or dual-dye experiments where there is no suitable reference for a channel or array. Relevant "hits"'are -defi~n:ed as expression levels or amounts that characterize a specific experimental condition. Usually, these are nucleic acids or proteins in which the expression levels differ significantly between different experimental conditions, usually by comparison of the expression levels of a nucleic acid or protein in the different conditions and analyzing.the relative expression ("fold change") of the nucleic acid or protein and the ratio of its expression level in one set of samples to its expression in another set.
Data obtained from microarray experiments can be analyzed by any one of numerous statistical analyses, such as clustering methods and scoring methods.
Clustering methods attempt to identify targets (such as nucleic acids and/or proteins) that behave similarly across a range of conditions or samples. The motivation to fmd such targets is driven by the assumption that .targets that demonstrate similar patterns of expression shar..e common characteristics, such as common regulatory elements, comm.on functions, or common cellular origins.
Hierarchical clustering is an agglomerative process in which single-member clusters are fused to bigger and bigger clusters. The procedure begins by computing a pairwise distance matrix between all the target molecules, the distance matrix is explored for the nearest genes, and they are defined as a cluster. After a new cluster is formed by agglomeration of two clusters, the distance matrix is updated to reflect its distance from all other clusters.
Then, the procedure searches for the nearest pair of clusters to agglomerate, and so on. This procedure results in a hierarchical dendrogram in which multiple clusters are fused to nodes according to their similarity, resulting in a single hierarchical tree. Hierarchical clustering software algorithms include Cluster and Treeview.
K-means clustering is an iterative procedure that searches for clusters that are defined in terms of their "center" points or means. Once a set of cluster centers is defined, each target molecule is assigned to the cluster it is closest to. The clustering algorithm then adjusts the center of each cluster of genes to minimize the sum of distances of target molecules in each cluster to the center. This results in a new choice of cluster ceiiters, and target molecules can be reassigned to clusters. These iterations are applied until convergence is observed. Self-organizing maps (SOMs) are related in part to the k-means procedure, in that the data is assigned to a predetermined set of clusters. However, unlike k-means, what follows is an iterative process in which gene expression vectors in each cluster are "trained" to find the best distinctions between the different clusters. 'In other words, a partial siructure is=imposed on the 'data and then this structure is iteratively modified according to the data. SOM is included in many software packages, such as, for instance, GeneClu$ter. Other clustering- methods include. graph-theoretic clustering, which utilizes graph-theoretic and statistical techniques to identify tight groups of highly similar elements (kernels), which are likely to belong to the same true cluster. ' Several heuristic procedures are then used to expand the kernels into the full clustering. An example of software utilizing graph-theoretic clustering includes CLICK in combination with the-Expander visualization tool.
Data obtained from high-throughput expression analyses cary be scored using statistical methods such as parametric and non-parametric methods. Parametric approaches model expression profiles within a parametric representation and ask how different the parameters of the experimental groups are. Examples of parametric methods include, without limitation, 1-tests, separation scores, and Bayesian t-tests. Non-parametric methods involve analysis of the data, wherein no a priori assumptions are made about the distribution of expression profiles in the data, and the degree to which the two groups of expression measurements are distinguished is directly examined. Another method uses the TNOM, -or the threshold number of misclassifications, which measures the success in separation two groups of samples by a simple threshold over the expression values.
= SAGE (serial analysis of gene expression) can also be used to systematically determine the levels of gene expression. In SAGE, short sequence tags within a defined position containing sufficient information to uniquely identify a transcript are used, followed by concatenation of tags in a serial fashion. See, for example, Velculescu V.E. et al, (1995) Science 270: 484-487.
Polyadenylated RNA is isolated by oligo-dT priming, and cDNA is then synthesized using a biotin-labeled primer. The cDNA is subsequently cleaved with an anchoring restriction endonucleases, and the 3'-terminal cDNA fragments are bound to streptaviding-coated beads.
.An oligonucleotide linker containing recognition sites for a tagging enzyme is linked to the bound cDNA. The tagging enzyme can be a class II restriction endonucleases that cleaves the DNA at a constant number of bases 3' to the recognition site, resulting in the release of a short tag and the linker from the beads after digestion with the enzyme. The 3' ends of the released tags plus linkers are then blunt-ended and ligated to one another to form linked ditags that are approximately 100 base pairs in length. The ditags are then subjected to PCR
amplification, after which the linkers and tags are released by digestion with the anchoring restriction endonucleases. Thereafter, the tags (usually ranging iii size from 25-30-mers) are gel purified, concatenated, and cloned into a sequence vector. Sequencing the coneatemers enables individual tags to be identified and the abundanee:of the transcripts for a given cell or tissue type can be determined. . `
The DBMARKER proteins, polypeptides, mutations, and polymorphisms thereof can be detected in any iuanner known to those skilled in the art. Of particular utility are two-dimensional gel =electrophoresis, which separates a mixture of proteins (such as found in biological samples such as serum) in one dimension according to the isoelectric point (such as, for example, a pH range from 5-8), and according.to molecular weight in a second dimension.
Two-dimensional liquid chromatography is also advantageously used to identify or detect DBMARKER proteins, polypeptides, mutations, and polymorphisms of the invention, and one specific example, the ProteomeLab PF 2D Protein Fractionation System is detailed in the ..Examples. The PF 2D system resolves proteins in one dimension by isoelectric point and by hydrophobicity in the second dimension: Another advantageous method of detecting proteins, polypeptides, mutations, and polymorphisms include SELDI (disclosed herein) and other high-throughput proteomic arrays.
DBMARKER proteins, polypeptides, mutations, and polymorphisms can be typically detected by contacting a sample from the subject with an antibody which binds the DBMARKER
protein, polypeptide, mutation, or polymorphism and then detecting the presence or absence of a reaction=product. The antibody may be monoclonal, polyclonal, chimeric, or a fragment of the foregoing, as discussed in detail above, and the step of detecting the reaction product may be carried out with any suitable immunoassay. The sample from the subject is typically a biological fluid as described above, and may be the same sample of biological fluid used to conduct the methodi=described above.
Imznunoassays carried out in accordance with the present invention may be homogeneous assays or heterogeneous assays. In a homogeneous assay, the immunological reaction usually involves the specific antibody (e.g., anti-DBIVIARKER protein antibody), a labeled analyte, and the sample of interest. The signal arising from the label is modified, directly or indirectly, upon the binding of the antibody to the labeled analyte. Both the immunological reaction and detection of the extent thereof can be carried out in a homogeneous solution.
Immunochemical labels which may be employed include free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages, or coenzymes.
In a heterogeneous assay approach, the reagents are usually the sample, the antibody, and means for producing a. detectable signal. Samples as described above may be used. The antiliody can be immobilized on a support, such as a bead (such as:protein A agarose, protein G agarose, latex, polystyrene, magnetic or paramagnetic beads), plate or slide, and contacted with the specimen suspected of containing the antigen in a liquid phase. The support is then separated from the liquid phase and either the support phase or the-liquid phase is examined for a detectable signal employing means for producing such signal. = The signal is related to the-:
presence of the analyte in the sample. Means for producing a detectable signal include the use of radioactive labels, fluorescent labels, or enzyme labels. For :exarnple, if the antigen to be detected contains a second binding site, an antibody which binds to that site can be conjugated to a detectable group and added to the liquid phase reaction solution before the separation step.
The presence of the detectable group on the solid support indicates the presence of the antigeii in the test sample. Examples of suitable immunoassays are oligonucleotides, immunoblotting, immunoprecipitation, immunofluorescence methods, chemiluminescence methods, electrochemiluminescence or enzyme-linked immunoassays.
Those skilled in the art will be familiar with numerous specific immunoassay formats and variations theredf which may be useful for carrying out the method disclosed herein. See generally E. Maggio, Enzyme-Immunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see also U.S. Pat. No. 4,727,022 to Skold et al. titled "Methods for Modulating Ligand-Receptor Interactions and their Application," U.S. Pat. No. 4,659,678 to Forrest et al.
titled "Irnrnunoassay of Antigens," U.S. Pat. No. 4,376,110 to David et al., titled "Immunometric Assays Using Monoclonal Antibodies," U.S. Pat. No. 4,275,149 to Litman et al., titled `:Macromolecular Environment Control in Specific Receptor Assays," U.S. Pat. No. 4,233,402 to Maggio et al., titled "Reagents and Method Employing Channeling," and U.S. Pat. No. 4,230,767 to Boguslasld et al., titled "Heterogenous Specific Binding Assay Employing a Coenzyme as Label."

Antibodies can be conjugated to=-a solid support suitable for a diagnostic assay (e.g., beads such as protein A or protein G agarose, microspheres, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as passive binding. Antibodies as described herein may likewise be conjugated to detectable labels or groups such as radiolabels (e.g., 355, 125I, 131I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein, Alexa, green fluorescent protein) in accordance W-ith known techniques.
Antibodies can also be useful for detecting post-translational modifications of DBMARKER proteins, polypeptides, mutations, and polyinorphisms, such as tyrosine phosphorylation, threonine phosphorylation, serine phosphorylation, glycosylation (e.g., 0-G1cNAc), Such antibodies specifically detect the phosphorylated amino acids in a protein or proteins of interest, and can be used in immunoblotting, immunofluorescence, and ELISA assays described herein. These antibodies are well-known to those skilled in the art, and commercially available: Post-translational modifications can also be determined using metastable ions in reflector matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) (Wirth, U. et al. (2002) Proteomics 2(10): 1445-51).
For DBMARKE.R proteins, polypeptides, mutations, and polymorphisms known to have enzymatic activity, the activities can be determined in vitro using enzyme assays known in the art. Such assays include, without limitation, kinase assays, phosphatase assays, reductase assays, among many others. Modulation of the kinetics of enzyme activities can be determined by measuring the rate constant Km using known algorithms, such as the Hill plot, Michaelis-Menten equation, linear regression plots such as Lineweaver-Burk analysis, and Scatchard plot.
Using sequence information provided by the database entries for the DBMARKER
sequences, expression of the DBMARKER sequences can be detected (if present) and measured using techniques well known to one of ordinary skill in the art. For example, sequences within the sequence database entries corresponding to DBMARKER sequences, or within the sequences disclosed herein, can be used to construct probes for detecting DBMARKER RNA
sequences in, e.g., Northern blot hybridization analyses or methods which specifically, and, preferably, quantitatively amplify specific nucleic acid sequences. As another example, the sequences can be used to construct primers for specifically amplifying the DBIVIARKER
sequences in, e.g., amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR). When alterations in gene expression are associated with gene amplification, deletion, polyrnorphisms, and mutations, sequence comparisons in test and reference populations can be made by comparing relative amounts of the examined DNA sequences in the test and reference cell populations.
Expression of the genes disclosed herein can be measured at the RNA level using any method known in the art. For example, Northern hybridization analysis using probes which specifically recognize one or more of these sequences can be used to determine gene expression.
Alternatively, expression can be measured using reverse-transcription-based PCR assays (RT-PCR), e.g., using primers specific for the differentiallyexpressed sequences.
Alternatively, DBMARKER protein and niacle.ic acid metabolites or fragments can be measured. The term "metabolite" includes any chemical or biochemical product of a metabolic process, such as any compound produced by the processing, cleavage or consumption, of a biological molecule (e.g., -a protein, nucleic acid, carbohydrate, or lipid).
Metabolites can be detected in a variety of ways known to one of skill in the art, including the refractive index -spectroscopy (RI), ultra-violet spectroscopy (UV), fluorescence analysis, radiochemical analysis, near-infrared spectroscopy (near-IR), nuclear magnetic resonance spectroscopy (NMR), light scattering analysis (LS), mass -spectrometry, pyrolysis inass spectrometry, nephelometry, dispersive Raman spectroscopy, gas chromatography combined with mass spectrometry, liquid chromatography combined with mass spectrometry, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) combined with ma.ss spectrometry, surface-enhanced laser desorption ionization (SELDI), ion spray spectroscopy combined with mass spectrometry, capillary electrophoresis, NMR and IR detection. (See, WO 04/056456 and WO
04/088309, each of which are hereby incorporated by reference in their entireties) In this regard, other DBMARI{ER analytes can be measured using the above-mentioned detection methods, or other methods known to the skilled artisan.
Kits The invention also includes a DBMARKER-detection reagent, e.g., nucleic acids that specifically identify one or more DBMARKER nucleic acids by having homologous nucleic acid sequences, such as oligonucleotide sequences, complementary to a portion of the DBMARKER
nucleic acids or antibodies to proteins encoded by the DBMARI~CER nucleic acids packaged together in the form of a kit. The oligonucleotides can be fragments of the DBMARKER genes.
For example the oligonucleotides can be 200, 150, 100, 50, 25, 10 or less nucleotides in length.

The:DBIv1ARKER-detection reagents can also comprise, inter alia, antibodies or fragments of antibodies, and aptamers. The kit may contain in separate containers a nucleic acid or antibody (either already bound to a solid matrix or packaged separately with reagents for binding them to the matrix), control formulations (positive and/or negative), and/or a detectable label.
Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay may be included in the kit. The assay may for example be in the fonn of a Northern blot hybridization or a saiidwich ELISA as known in the art: Alternatively, the kit can be in the form of amicroarray as =..
known in the art.
Diagnostic kits for carrying out -the methods described herein are produced in a. number of ways: Preferably, the kits of the present invention comprise a control (or reference) sample.
derived from a subject having normal glucose levels. Altematively, the kits can comprise a control sample derived from a siu.bject who has been diagnosed with or identified as suffering frotn type 2 Diabetes or a pre-diabetic condition. In one embodiment, the diagnostic kit comprises (a) an antibody (e.g., fibrinogen aC domain peptide) conjugated to a solid support and (b) a second antibody of the invention conjugated'to a detectable group.
The reagents may also include ancillary agents such as-buffering agents.and. protein stabilizing agents, e.g., polysaccharides and the like. The diagnostic kit may further include, where necessary, other members of the signal-producing system of which system the detectable group is a member (e.g., enzyme substrates), agents for reducing background interference in a test, control reagents;
apparatus for conducting a test, and the like. Alternatively, a test kit contains (a) an antibody , and (b) a specific binding partner for the antibody conjugated to a detectable group. The test kit may be packaged in any suitable manner, typically with all elements in a single container, optionally with a sheet of printed instructions for carrying out the test.
For example, DBMARKER detection reagents can be immobilized on a solid matrix such as a porous strip to form at least one DBMARKER detection site. The measurement or detection region of the porous strip may include a plurality of sites containing a nucleic acid. A test strip may also contain sites for negative and/or positive controls. Alternatively, control sites can be located on a separate strip from the test strip. Optionally, the different detection sites may contain different amounts of immobilized nucleic acids, e.g., a higher amount in the first detection site and lesser amounts in subsequent sites. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication of the amount of DBMARKERS..,present in the sample. The detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a test strip.
Alternatively, the kit contains a nucleic acid substrate array comprising one or more nucl eic acid sequences. The nucleic acids on the array specifically identify one or more nucleic acid sequences represented by DBMARKERS 1-158. In various embodiments, the expression of 2, 3,4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, or more of the DBMARKERS 1-158 can be identified by virtue of binding to the array. The substrate array can be on, e.g.,'a solid substrate, e.g., a "chip" as described in U.S. Patent 14o.5,744,305. Alternatively, the substrate array can be, a solution array, e.g., xMAP (Luminex, Austin,.TX), Cyvera (Illumina, San Diego, CA), CellCard- (Vitra Bioscience, Mountain View, CA) and Quantum Dots' Mosaic (Invitrogen, Carlsbad, CA).. The skilled artisan can routinely make antibodies, nucleic acid probes, e.g., oligonuclebtides, aptamers, siRNAs, antisense oligonucleotides, against any of the DBMARKERS in:Table 1. The Examples presented herein describe generation of monoclonal antibodies in mice,.,as well as generation of polyclonal hyperimmune serum from rabbits. Such techniques are well-known to those of ordinary skill in the art.

Pharmaceutical Cotnpositions and Methods of Treatment The terrn "treating" in its various grammatical forms in relation to the present invention refers to preventing (i.e. chemoprevention), curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression, disease causative agent (e.g., bacteria or viruses) or other abnormal condition. For example, treatment may involve alleviating a symptom (i.e., not necessarily all symptoms) of a disease or attenuating the progression of a disease.
As used herein, the term "therapeutically effective amount" is intended to qualify the amount or amounts of DBMARKERS or other diabetes-modulating agents that will achieve a desired biological response. In the context of the present invention, the desired biological response can be partial or.total inhibition, delay or prevention of the progression of type 2 Diabetes, pre-diabetic conditions, and complications associated with type 2 Diabetes or pre-diabetic conditions; inhibition, delay or prevention of the recurrence of type 2 Diabetes, pre-diabetic conditions, or complications associated with type 2 Diabetes or pre-diabetic conditions;
or the prevention of the onset or development of type 2 Diabetes, pre-diabetic conditions, or complications associated with type 2 Diabetes or pre-diabetic conditions (chemoprevention) in a subject, for example a human.

The DBMARKERS, preferably included as part of a pharmaceutical composition, can be adnainistered by any known administration method knbwn to a person skilled in the art.
Examples of routes of administration include but are not limited to oral, parenteral, intraperitoneal, intravenous, intraarterial, transderrnal, topical, sublingual, intramuscular, rectal, transbuccal, intranasal, liposomal, via inhalation, vagirial, intraoccular, via local delivery by catheter or stent, subcutaneous, intraadiposal, intraarticular; intrathecal, or in a slow release dosage form. The DBMARKERS or pharrnaceutical compositions comprising the DBMARKERS- can be administered in accordance with any dose and dosing schedule that achieves a dose effective to treat disease.
As examples, DBMARKERS or pharmaceutical compositions comprising DBMARKERS of the invention can be administeted in such oral forms as tablets, capsules (eacli of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, the.
DBMARKERS or - -pharmaceutical compositions comprising DBMARI{ERS can be administered by intravenous (e.g., bolus or infusion), intraperitoneal, subcutaneous, intramuscular, or other routes using forms well known to those of ordinary skill in the pharmaceutical arts.
DBNIA.RKERS and pharmaceutical compositions comprising DBMARKERS can also be administered in the form of a depot injection or implant preparation, which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. hnplants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.
DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large i.unilamellar vesicles and miiltilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Liposomal preparations of diabetes-modulating agents may also be used in the methods of the invention.

DBMARKERS or pharmaceutical compositions-_comprising DBNIARKERS can also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be prepared with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyi-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol,.or polyethylerieoxide-polylysine substituted with pahnitoyl residues. Furtherrnore, DBMARKERS or pharmaceutical compositions comprising DBMARKERS can be prepared with biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
The DBMARKERS or pharmaceutical compositions comprising DBMARKERS can also be administered in intranasal form-via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intennittent throughout the dosage regime.
Suitable pharmaceutically acceptable salts of the agents described herein and suitable for use in the method of the invention, are conventional non-toxic salts and can include a salt with a hase or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., lithium salt, sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an anunonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylantine salt, N,N'-dibenzylethylenediamine salt, etc.) etc.; an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an or.ganic carboxylic or sulfonic acid addition salt (e.g., forrnate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.) and the like.
In addition, this invention also encompasses pharmaceutical compositions comprising any solid or liquid physical form of one or more of the DBMARKERS of the invention. For example, the DBMARKERS can be in a crystalline form, in amorphous form, and have any particle size. The DBMARI.~ER particles may be micronized, or may be agglomerated, particulate granules, powders, oils, oily suspensions or any other form of solid or liquid physical form.
For oral administration, the pharmaceutical compositions can be liquid or solid. Suitable solid oral formulations include tablets, capsules, pills, granules, pellets, and the like. Suitable liquid oral formulations include solutions, suspensions, .dispersions, emulsions, oils, and tlie like.
Any inert excipient that is commonly usecl as a carrier or diluent may be used in the formulations of the present invention, such as= for example, a gum, a starch, a sugar, a cellulosic material; an acrylate, or mixtures thereof. The.compositions may fuxther comprise a disintegrating agent and a lubricant, and in addition may coinprise one or more additives selected frbm a binder, a buffer, a protease inhibitor, a surfactant, a solubilizing agent, a plasticizer, an emulsifier, a stabilizing agent, a viscosity increasing agent, a sweetener, a film forming agent, or any combination thereof. Furthermore, the compositions of the present invention. may be in the fomi of controlled release or imrnediate release. foxmulations.
DBMARKERS can be administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier"
materials or "pharmaceutically acceptable carriers") suitably selected with respect to the intended form of administration. As used herein, "pharmaceutically acceptable carrier or .20 diluent" is intended to include any and all=solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference.
For liquid formulations, pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
Aqueous carriers include water, alcoholic/aqueous solutions, emulsions, or suspensions, including saline and buffered media. Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil. Solutions or suspensions can also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite;
chelating agents such as ethylenediaxninetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of ..such media and agents for pharmaceutically active substances is well known in the art. Except =insofar as any conventional media or agent is incompatible ~vith the active compound, use thereof in the- compositions is contemplated: Supplementary active compounds can also be, incorporated into the compositions.
Solid carriers/diluents include, but are not limited to, =a gum, a starch (e.g., corn starch, pregelatinized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material :(e:g.,:microcrystalline cellulose), an acrylate (e.g.; polymeth.ylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
In addition, the compositions may further comprise binders (e.g., acacia, conistarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl meth.yl' celluiose, povidone), disintegrating agents (e.g., comstarch, potato starch, alginic acid; silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate, Primogel), buffers (e.g., tris-HCI, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces; =detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol), a glidant (e.g., colloidal silicon dioxide), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g., hydroxypropyl cellulose, hydroxypropylmethyl cellulose), viscosity increasing agents (e.g., carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum), sweeteners (e.g., sucrose, aspartame, citric acid), flavoring agents (e.g., peppermint, methyl salicylate, or orange flavoring), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants (e.g., stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g., colloidal silicon dioxide), plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers (e.g., carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines), coating and film forming agents (e.g., ethyl cellulose, acrylates, polymethacrylates) and/or adjuvants.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elirnination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza.
Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted"to infected cells with monoclonal antibodies to viral antigens) can also b.e used as pharmaceuticall.y acceptable carriers. These can,be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No.
4,522,811.
It is especially advantageous to formulate oral compositions in dosage unit form for ease of adxninistration and uniformity of dosage. Dosage unit form as used herein refers to physically' discrete units- suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit . ..
forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals. The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
The preparation of pharmaceutical compositions that contain an active component is well understood in the art, for example, by mixing, granulating, or tablet-forming processes. The active therapeutic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. For oral administration, the active agents are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic, or oily solutions and the like as detailed above. For IV administration, Glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH
range acceptable for intravenous admixiistration can be used as buffers.
Sodium chloride solution wherein the pH has been adjusted to the desired range with either acid or base, for example, hydrochloric acid or sodium hydroxide,. can also be employed. Typically, a pH
range for the intravenous formulation can be in the range of from about 5 to about 12. A
particular pH range for intravenous formulation comprising an HDAC inhibitor, wherein the HDAC
inhibitor has a hydroxamic acid moiety, can be about 9 to about 12.
Subcutaneous formulations can be prepared according to procedures well kriown in the art at a pH in the range between about 5 and about 12, which include suitable buffers and isotonicity agents. They can be fornmuiated to deliver a daily dose of the active agent in one or more daily subcutaneous administrations. The choice of appropriate. buffer and pH of a formulation, depending on solubility of one or more DBnIARKERS to be ad.rrministered, is : readily made by a person having ordinary skill in the art. Sodium chloride solution wherein the pH has been adjusted to the desired range with either acid or base, for example, hydrochloric acid or sodium hydroxide, can also be employed in the subcutaneous formulation. Typically, a pH range for the subcutaneous formulation can be in the range of from about 5-to about 12.
The compositions of the present invention can also be administered in intranasal form via 15.. topical use of suitable intranasal vehicles, or via transdermal routes, using those fonms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.

EXAMPLES
Example 1: Biomarker Identification in the Cohen rat model of Type 2 Diabetes The Cohen diabetic (CD) rat is a well-known and versatile animal model of Type Diabetes, and is comprised of 2 rodent strains that manifest many of the common features of Type 2 Diabetes (T2D) in humans. The sensitive strain (CDs) develops Diabetes within 30 days when maintained on a high sucrose/copper-poor diet (HSD), whereas the resistant strain (CDr) retains normal blood glucose levels. When maintained indefinitely on regular rodent diet (RD), neither strain develop symptoms of T2D.

Sample Preparation Serum, urine, and tissue samples (including splenic tissue, pancreatic tissue, and liver tissue) were obtained from both CDr and CDs rats that were fed either RD or HSD for 30 days.
The samples were flash-frozen and stored at -80 C.

Whole protein extracts were prepared for each of the 4 experimental conditions, utilizing individual organs per group. Pancreatic tissues were processing using a mechanical shearing device (Polytron). To preserve protein integrity in processed samples, tissues were kept on dry ice until processing commenced and all buffers and equipriment were pre-chilled. Samples were 5 also kept on ice during the homogenization process.
T-Per buffer (Pierce) was pre-Lchilled on ice and two tablets of Complete Protease Inhibitor (Roche Applied Sciences) were added per 50 m,l of buffer prior to use. * Once protease inhibitors, were added, any unused buffer was discarded. T-Per buffer was used at 20 nil per gtam of.tissue. For each group, pancreatic samples were weighed and the amount of lysis buffer 10 required was calculated and added to each tissue sample in a 50 ml tube.
Each sample was homogenized on ice for 10 seconds, followed by a 30 second rest period to allow the sample to cool. If gross debris was still apparent, the cycle was'repeated until the homogenate was smooth.
The horriogenization probe was inserted into the samples approximately I cm from the bottom of the-tube to rninimize foaming. When homogenization was complete, the extract was centrifuged at 10,000 x g for 15 minutes at 4 C. Following centrifugation, the supernatant was harvested and a bicinchoninic acid (B CA) assay was: performed to determine the total protein content. Table 2 provides the mean protein content of the samples corresponding to CDr rats fed either RD or HSD, and CDs rats fed either RD or HSD.
Table 2: Total Protein Content of Pancreatic Extracts from Cohen Diabetic Rats Mean Protein Content (Rgtml) Tissue CDr-RD CDr-HSD CDs-RD CDs-HSD
Pancreas 7969.2 6061.9 6876.4 3387.8 Supernatants were dispensed into aliquots and stored at -80 C. Pelleted material was also kept and stored at -80 C.
Protein expression profiling of the CDr and CDs phenotypes was conducted on the pancreatic extracts using one-dimensional SDS-PAGE. A sample of each extract containing 6 gg of total protein was prepared in sample buffer and loaded onto a 4-12%
acrylamide gel.
Following completion of the electrophoretic run, the gel was soaked with Coomassie stain for 1 hour and destained in distilled water overnight. The resulting protein expression profile allowed an empirical visual comparison of each extract (Figure 1). These pancreatic extracts were then used for bi-directional immunological contrasting, disclosed herein.
Since albumin, immunoglobulin and other abundant proteins constitute about 95-97% of the total proteins in serum, the detection of less abundant proteins and peptides markers are masked if the whole serum were analyzed directly. Therefore, fractionation of serum samples was necessary to reduce masking of low abundance protein and to increase the number of peaks available= for analysis.
To increase the detection of a larger nurriber of peaks as well as to alleviate signal suppression e:ffects`on low abundance proteins from high abundant proteins such as albumin, immunoglobulin etc., the crude serum samples from CDr and CDs rats fed RD or HSD were fractionated into=six fractions. The fractionation was carried out using anion exchange bead based serum fractionate kit purchased from Ciphergen (Fremont, CA). In brief, the serum samples were diluted with a 9M urea denaturant-solution; the diluted.samples were then loaded =' onto a 96-well -filter micropfate pre-filled with an anion exchange sorbent.
Using this process, samples were allowed to bind to the active surface of the beads, and after 30 minutes incubation at 4 C, the samples'were eluted using.stepwise pH gradient buffers. The process allowed the collection of 6 fractions including pH 9, pH 7, pH 5, pH 4, pH 3 and an organic eluent. After the fractionation, the serum samples were analyzed in the following formats on SELDI chips.

SELDI (Surface Enhanced Laser Desorption Ionization) SELDI Proteinchip Technology (Ciphergen) is designed to perform mass spectrometric analysis of protein mixtures retained on chromatographie chip surfaces. The SELDI mass spectrometer produces spectra of complex protein mixtures based on the mass/charge ratio of the proteins in the mixture and their binding affinity to the chip surface.
Differentially expressed proteins are determined from these protein profiles by comparing peak intensity. This technique utilizes aluminum-based supports, or chips, engineered with cheznical modified surfaces (hydrophilic, hydrophobic, pre-activated, normal-phase, immobilized metal affinity, cationic or anionic), or biological (antibody, antigen binding fragments (e.g.; scFv), DNA, enzyme, or =
receptor) bait surfaces. These varied chemical and biochexnical surfaces allow differential capture of proteins based on the intrinsic properties of the proteins themselves. Tissue extractions or body fluids in volumes as small as I l are directly applied to these surfaces, where proteins with affinities to the bait surface will bind. Following a series of washes to remove non-specifically or weakly bo-und proteins, the bound proteins are laser desorbed and ionized for MS
analysis. Molecular weights of proteins ranging from small peptides to proteins (1000 Dalton to 200 kD) are measured. These mass spectral patterns are then used to differentiate one sample from another, and identify lead candidate markers for fu.rther analysis.
Candidate marker have been identified by comparing the protein profiles of conditioned versus conditioned stem cell culture medium. Once candidate markers are identified, the.y are purifzed and sequenced.
The fractionated serum samples were applied to different chemically modified surface chips (cationic exchange, anionic exchange, metal-affinity binding, hydrophobic and normal phase).and profiled by SELDI, two-dimensional-PAGE (2DE) and two-dimensional liquid chromatography (2D/LC).

Two-dimensional Liquid Chromatography (2D/LC) The ProteomeLab PF-2D Protein Fractionation System is a fully automated, two-dimensional fractionation system (in liquid phase) that.resolves and collects proteins by isoelectric point (pI) iri the first dimension and by hydrophobicity in the second'dimension. The.
system visualizes the complex pattern with a two dimensional protein map that allows the direct comparison of protein profiling between different samples.: Since all components are isolated and collected in liquid phase, it is ideal for downstream protein identification using mass spectrometry and/or protein extraction for antibody production.
The PF 2D system addresses many of the problems associated with traditional proteomics research, such as detection of low abundance proteins, run-to-run reproducibility, quantitation, detection of membrane or hydrophobic proteins, detection of basic proteins and detection of very low and very high molecular weight proteins. Since the dynamic range of proteins in serum spans over 10 orders of magnitude, and the relatively few abundant proteins make up over 95%
of the total protein contents, this makes it very difficult to detect low abundant proteins that are candidate markers. In order to enrich and identify the less abundant proteins, the serum samples were partitioned using IgY-R7 rodent optimized partition column to separate the seven abundant proteins (Albumin, IgG, Transferrin, Fibrinogen, IgM, at-Antitrypsin, Haptoglobin) from the.
less abundant ones.
The partitioned serum was applied to the PF-2D. The first dimensional chromatofocusing was performed on an HPCF column with a linear pH gradient generated using start buffer (pH 8.5) and eluent buffer (pH 4.0). The proteins were separated based on the pT.

Fractions were collected and applied:to a reverse-phase HPRP column for a second dimensional separation. The 2D map generated from each sample was then compared and differential peak patterns were identified. The fraction was subsequently selected and subjected to trypsin digestion. The digested samples were sequenced using LC/MS for protein identification.
2-D GeI Electrophoresis Two-dimensional electrophoresis has the ability to resolve complex mixtures of ' thousands of proteins simultaneously iii -a single gel. In the first dimension, proteins are separated by pI, while in the second dimension, proteins are sepaiated by MW.
Applications of 2D gel electrophoresis include proteome analysis, cell differentiation, detection of disease markers, monitoring response to treatment etc.
The IgY partitioned serum samples were applied to imrniobilized pH gradient (IPG) strips with different pH gradients, pH 3-10,=pH 3-6 and pH 5-8. After the first dimensional run, the IPG strip was laid on top of an 8-16% or 4-20% SDS-PAGE gradient. gel for second dimensional separation.

Results A peak protein of approximately 4200 daltons was present in the senum of CDr-RD and CDr-HSD, but not in the serum of CDs-RD or CDs-HSD, as shown in Figure 2A.
Figure 2B is a MS/MS spectrum of the 4200 dalton fragment. This protein was sequenced and following extensive database searches, was found to be a novel protein. The peptide was designed "D3"
and its sequence was found to be SGRPP MIVWF NRPFL IAVSH THGQT ILFMA KVINP
VGA (SEQ ID NO: 1). The D3 peptide.is a 38-mer peptide sequence that corresponds to the first bibmarker discovered in the Cohen diabetic rat. Sequence alignment using the BLAST
algorithm available from the National Center for Biotechnology Information (NCBI) was performed and the 38-amino acid fragment was found to have sequence identity with at least ten different amino acid sequences. Notably, BLAST alignment revealed that the 38-amino acid D3 peptide contains conserved motifs corresponding to: "FNRPFL" and "FMS/GKVT/VNP".
Figure 3A shows the results of the BLAST alignment of aniino acid sequences related to the D3 peptide fragment, and Figure 3B shows the results of a BLAST alignment of nucleic acid sequences encoding the D3 peptide and the peptides identified by protein BLAST. Degenerate primers were designed to target the conserved motifs and comprise the following sequences:

Forward primer (targeting regions containing the amino acid sequence "FNRPFL":
5'-TTC AAC
MRR CCY TTY ST-3' (SEQ ID NO: 2) and Reverse primer (targeting regions containing the sequence "FMS/.GKVT/VNP"): 5'-YVA CYT TKC=YMA KRA AGA-3' (SEQ ID NO: 3);
wherein M= A or C; R= A or G; Y= C or T; S= C. or G; K= G or T; and V= A, C, or G.
These degenerate primers were used in reverse-transcription polymerase chain reactions (RT-PCR) to amplify human SERPINA 3 in liver and pancreas. A 1.3 Kb fragment was identified in humari liver and pancreas, as shown in Figure 3C.
Table 3 represents additional identified candidate markers identified by SELDI
analysis.
Array = CM10 (Anion Type exchange) Sample Fractioned Serum Fl CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-2156 + . +
-2270 + + - +
-3875 + + - -Sample Fractioned Serum F3 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-3408 - + - +
-3422 + - + --3848 - + - - +
-3861 + - + -Sample Fractioned Serum F4 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-4202 + - + -~4423 + +
Sample Fractioned Serum F5 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-5377 ++ = ++ ++ +
-5790 +/- = '+/- - a--8813 +
Sample Fractioned Serum F6 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD

-4200 + - + Sample Whole Serum CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-6631 - + - --7013 - - + +
-7027 + + - --7811 - + -Array Type Q10 Sample Fractioned =Serum Fl CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-2627 + - + : --2705 + - + --4290 + + -+-+= . _ +
=~5058 - - + --5220 + ++ +
-5789 - - +
-8818 + +/- ++ ++
Sample Fractioned Serum F2 CDs-MIZ CDr-RD RD CDr-HSD CDs-HSD
-2359 + +I- - --2587 + + - +/--2879 + + - +/----2298 - + - -Sample Fractioned Serum F4 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-4200 + - + --2067 - - + +
-2092 - - + +
-2042 - ~ + +=
-8810 - - + +
-8850 + + - -Sample Fractioned Serum F5 CDs-IVllZ CDr-RD RI) CDr-HSD CDs-HSD
-3977 + - + --4200 + - + --2102 + - + --4030 + -+-t- + ++
Sample Fractioned Serum F6 CDs- -M/Z CDr-RD RD CDr-HSD. CDs-HSD
-4200 + - 4= - --17645 + - + -Sample Whole Serum CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-6632 - + - --3419 + +
-3435 . + + --4074 + + - --4090 + + - --4200 + - + ---5152 + + - --8915 + + - -Array Type H50 Samplc Fractioned Serum F2 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-5521 - + - -Sample Fractioned Serum F5 CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-34224 - - - +
Array Type IMAC
Sample Whole Serum =
CDs-M/Z CDr-RD RD CDr-HSD CDs-HSD
-2714 + + +
- 4330 - + + +

The differences among Cohen diabetic rats are shown in Figures 4A and 4B, which represent gels depicting biomarkers identified by LC/MS technology and a graph showing an elution profile obtained by differential two-dimensional reverse-phase HPLC or CDr-RD (red) versus CDs-RD (green) of a selected first dimension pI fraction (fraction 31).
Figure 5A
represent 2DE gels of samples derived from each of the four Cohen diabetic rat models, while Figure 5B is a magnified view of spots identified in Figure 4A identified "as apolipoprotein E, liver regeneration-related protein, and a previously unidentified protein.
Figure 6 is a graphical representation illustrating the differentially expressed proteizis found in the four Cohen Diabetic rat models using 2DE technology. Figure 7 is a histogram showing the differentially expressed Cohen Diabetic rat serum proteins identified by 2DE.
The D3 peptide was used for the production of hyper-immune serum in rabbits.
Figure 8 'depicts Western blots showing the reactivity of the D3 hyper-immune serum with a--4 kD
protein isolated from CDr-RD and CDr-HSD rat serum fraction 6. Fractionated CD
rat serum samples were run on a 10% SDS-PAGE gel, then transferred to PVDF membranes. A
higher molecular weight doublet (in the range of 49 and 62 kD) also reacted with the hyper-immune sera, indicated that a parent protein is expressed by all strains under treatment modalities RD or HSD, however a derivative of smaller size (-4 kD) corresponding to the D3 fragment is differentially expressed only in the CDr strain. These results are consistent with the results obtained by SELDI profiling. The concentration of the D3 fragment in CDr rat serum was subsequently analyzed by SELDI. A series of synthetic D3 peptide standards (0.1, 0.033, 0.011, 0.0037, 0.0012 and 0 mg/ml) and lOX diluted CDr-serum were spotted in duplicate on Q10 protein chip arrays. The peak intensity was plotted against the concentration of D3 peptide standards. Based on the plot (Figure 9), the linear range for concentration determination is from 0 to 0.01 mg/ml. Accordingly, the concentration of D3 in CDr-RD serum is around 0.04 mg/mi, based on the peak intensity of the CDr-RD serum sample.
Analysis of Serpina expression by Western blot analysis was performed in Cohen rat liver extracts using anti D3 rabbit serum (1:200) and secondary goat anti-rabbit IgG conjugated to HRP (1:25,000 dilution). Controls containing liver extracts (10 g) and secondary goat anti-rabbit IgG antibodies conjugated to HRP (1:25,000 dilution), but no primary antibody were also analyzed (Figure 10). A cluster of proteins (41, 45 and 47 kD) were visualized following reaction of liver extracts with D3 hyper immune serum. The 41 and 45 kD
proteins were expressed at approximately the same level while the 47kD protein is not detected in the diabetic rat-i.e., CDs-HSD (diabetic).
Table 4 contains a suirunary of biomarker data obtained from CD rat serum samples.

~ v~ =~ ~ = ~
o F :3 7 a j o o c p~ w d d t= N~ d A A ~ A A A A ~ ~
p ~ CV y, N N
o w w A ua r~ ri rs: cT. A
n, a a a~ w~' N a A
A =
0.Al OAO
y +
a ~ =
.~ .

ed_ ~
=!- + -f- -h ~
o U =

+ + -h t w ca =

p4 A
+ -{- + + + + u m 00 00 .-., n tn d= =a= e{ ~p V1 M O O O~ d~
c~ R' N v~ kn %O ,6 ~D n ~D
ee A N v'~ ~O N e~ ~D
t~n r~i V=
VG i} d' ~t d= C

00 vt~i ~
I.D N M N I'D 00 M v~ 00 M O~ ~O ~O -,Zi- N %O 00 tn 00 ~ GNC ~ l~ 00 vl N +N -/1 ~ kn ~ tr 1~~= ~ n M ~
n M Vn } N M I'O u'1 N
Cd O O=- ~ O N N
Rl-/"~1 v ~%] M C/] w Q Q n ~ d ~ L1. ~Y.

cG N
Q y ~.. N =C ~
~~ p C C V U p C
NC =~ ~ ~ ~-, V =a,_y., R ~ C ~ C_ N _O N
ta.
y. Q Q'= CV C ~ N O G O ~~ ~ b i" aQ-= i' Q 0. T C
~~=O o ~ F a ~ 7 =~ y ~ ~ ~ ~ = V ~F
A L ~ J vQi 1] f] O R R OU 0 E
a C=LI ~ C abi Q' G. LL ,^l. R v~ =. `C al ,- N.--. O t~..
~ O Q
~ =~ a=~
C
0. a O O C ~ O
o CL
d U E q F ce =y Q~
0 N e.'~ ~Y v1 ' ~O t~ o0 ii ~
a d Ex-~
A A A A Q A Q A
ci. ri ci v: A w n. a cli q A
0. 0. P, P w ~
t% G~HG 0.AH1 f~HA ~ ~ ~ ~ p~q + F
ca . ~ _.. ._ .
=~
.~ .
o + + + + + + + + + +

V
a .~ + + m 0.Ai ~ $ + $ =
E- E-S.

+ + + =i- + + + + 0.~1 pAq f~A + + + + + + + +
~ H H H

00 00 00 Vl Q~ N [, 00 M M ~ v1 N O CV v? ~n M N ~v1 et vl vi 'd= 00 N ~O ~G ,D oo 00 d O~
~ ~ N t- M f'Y M M h'= ~t" I~
M t~ I~ t~ ~/1 M h 00 00 cY p ~ Vl Vl O~ lD ^~ N
[~ O_ ~ O N 00 M M C h N l~ Q_l Q~ b o0 O~ O O h ti 00 v7 '~t O+ [- N =--00 N O M Ul [~ ~ v.y O O N O N
00 O O N 00 O 00 00 c*1 C? =-' ~/t O
%O N tn p N ~ I~ ~rf O N M O
yl y-~ w~ Vl M V1 N M ~O [~

N d ~= R" ~ v ~ p- L3' ¾ H ¾
~ Q d ~

C e o A g`, =E5 p n~ $ $~ b np a a~ c G ~, o Q
o 0o o T=~ c.~ C '0 ~= C a. H4U ~p7, ~ U E w n= r-L
o a p ~
a O
a V $ i => a. a 0 6 ~1 N Q .-a .y a~..

.01 ~ ,_õ N ..~.. = A ~D t~ a0 O~ O -N

E

F:
~

w w w w o w w w Q A A A w A A A
~
-.
. .
.. -ctl A + ~- + $ $ $ + + +
~
~

v ~
. ~
+ + $
~
, ~.
+ + + $ $ $ +

~D N 00 00 l- 00 . O ~D Vl vl vy v~
~p 00 00 %O [1-~ ~ ~ ~ 0~o h M ~n O V' r' . O~ W ~ ~O 00 O

N w O
N n tn V1 v1 G ~ O
z J C

c o `a M t,, o~ Q
t- ~ o~o o c~ a~i fl-o X "a U a co~ ~
rl 2 N N N N N N N

Example 2: Biomarker ldentification in Human Sera Analysis of human sera was performed using D3 hyper immune serum (rabbit;
Figure 11).
The primary antibody used was rabbit polyclonal antibodies produced following immunization with D3 peptide_ A protein with molecular weight of 20 kD (between the 14 kD
and 28 kD
markers) is expressed in human serum at a higher intensity in the normal individual as compared with Type 2 diabetic patient. A pair of proteins with MW of 60-80 kD appear to be present in both (normal and diabetic) samples. Interestingly, the intensity of the proteins in tlie doublet seemed to be inverted; an observation that was made using monoclonal antibodies derived from a ~ ==.
subtractive immunization with CDr-HSD and CDs-HSD pancreas. Figures 12A and 12B show preparative gels containing 100 g of CDr-HSD or'.CDs-HSD pancreatic extracts.
The positive control was stained with 20 g of anti-actin antibodies, and subclone lanes were stained with 600 l of conditioned culture supernatant (described elsewhere in this disclosure).
Human serum samples corresponding to=samples taken from normal, diabetic and insulin-resistant subjects were obtained from three differerit sources and subjected to SELDI analysis:
Dr. Itamar Raz, Dr. Wendell Cheatham, and Dr.= Rachel Danlrner. Dr. Raz's samples (hereinafter "Raz samples") comprised 11 T2D human serum and plasma samples, and 9 normal human serum and plasma samples. The Cheatham samples comprised a total of 51 serum and urine samples, 12 of which were derived from Type 1 Diabetic individuals, 13 from T2D individuals, 10 insulin=resistant subjects, and 16 normal subjects. The Dankner samples comprised 23 T2D
human serum samples and 25 normal human serum samples. SELDI analysis revealed the significant peaks from the Raz and Dankner samples, shown in Tables 5 and 6 below. Figure 13 is an example of whole human serum profiled on anionic Q10 chips by SELDI.
Table 5: Selected significant peaks present in Raz samples Sample No. Peak (MIZ) P-value Fold Change T2D/N) 1 12900 9.90E-07 3.24 2 134500 4.75E-06 0.55 3 44500 1.75E-05 2.21 4 4260 1.84E-05 0.4 5 4260 2.1=3E-05 0.49 6 56500 2.84E-05 0.55 7 6640 8.08E-05 2.14 8 12600 1.96E-04 2.64 9 2505 2.09E-04 1.71 10 29000 2.46E-04 0.63 Sample No. Peak (M/Z) P-value Fold Change (T2D/N) 11 3300 3.44E-04 0.65 12 14070 3.58E-04 0.69 13 11750 5.22E-Q4 2.81 14 6875 7.49E-04 2.2 15 13750 1.05E-03 0.66 16 9715 2.69E=03 1.89 17 9375 3.88E=03 1.61 18 6440 6.04E-03 2.1 Table 6: Selected significant peaks present in Dankner samples Sample No. Peak (M/Z) F-value . Fold Change (T2D/N) 1 10075 4:81E=04 3.63 2 9310 1.87E-03 1.9 3 4160 3.68E-03 1.74 4 6450 1.59E-04 0.76 9310 8.25E-04 1.36 6 7770 8.25E=04 0.66 7 6430 1.32E-'05 0.7 8 10650 2.25E-04 2.58 SELDI analysis revealed differentially expressed protein peaks identified in 5 human samples and 16 normal human samples. Figure 14 depicts a pseudogel view of SELDI
analysis of Fraction 1 of the samples. Each lane represents a spectrum of an individual sample from M/Z 14.0 kD to 16.0 kD. The M/Z for the protein bands are approximately 15.2, 14.8, and 14.5 kD, respectively. Figure 15 is another pseudogel view of SELDI analysis performed on 13 T2D and 16 normal fractionated serum samples (Fraction 3), profiled on a Q10 protein chip. =
Each lane represents the spectrum of an individual sample from M/Z 8.0 kD to 10.0 kD. The M/Z for the protein marker is approximately 9.3 kD. The graph below in Figure 15 is a cluster view of a marker (M/Z -6430) thaf is downregulated in T2D samples. Levels of albumin were profiled using SELDI on the Cheatham samples and were compared to the Dankner samples, as shown in Figure 16.
Example 3: Bi-Directional Imrnunolo ical Contrasting and Generation of Monoclonal Antibodies From the pancreatic extract protein profiles obtained by SDS-PAGE, obvious differences in the banding patterns were noted between CDr-HSD and CDs-HSD samples (Figure 1). Bi-directional immunological contrast was-performed between these two samples.
This technique involves injecting two pancreatic extracts from the Cohen diabetic rats to be contrasted separately into the footpads of an experimental animal (e.g. a Balb/c mouse).
Following uptake and processing..of the antigen at the site of injection by antigen presenting cells (APCs), the activated APCs migrate to the local lymph nodes (popliteal) to initiate an immune response. As these lymph nodes are located in each leg, they are anatomically separated.
from each other, which prevents mixing of antigen-specific lymphocytes.at this point. Later in the immune response, these activated lymphocytes migrate from the local lymph nodes to the spleen where they become mixed, and from where they may circulate systemically.
Two weeks after footpad injection, the animals were boosted by injecting each footpad with the same antigen as before. This boost-recalls antigen specific=
lymphocytes back to the site of injection, again subsequently draining to the popliteal lymph nodes. This technique uses the natural proliferation and cell migration processes as a filtering mechanism to separate and enrich specific lymphocytes in'each lymph node, where they are anatomically segregated to minimize mixing of cells that are specific for antigen(s) expressed in only one of the extracts. Three days after boosting; the popliteal lymph nodes were removed and separated into pools derived from each side of the animals. When boosting, it is imperative not to switch the antigenic material, as this will cause specific lymphocytes to migrate to both sets of popliteal lymph nodes and the anatomical segregation of specific cells, and hence the advantage of the technique, will be lost.
Fifteen female Balb/c mice ages 6-8 weeks were ordered from Harlan. Each animal was injected with 25 g of CDr-HSD pancreatic extract into the left hind footpad, and 25 g of CDs-HSD pancreatic extract into the right hind footpad. Antigens were prepared in 20% Ribi adjuvant in a final volume of 50 i as follows:
Table 7:
Right footpad Left footpad 375 mg of CDs-HSD 110 1 -----------375 mg of CDr-HSD ----------- 62 1 PBS 490 1 538 1 Ribi adjuvant 150 1 150 gl Ribi adjuvant was warmed to 37 C and reconstituted with I ml of sterile PBS.
The bottle was vortexed for at least 1 nvnute to fully reconstitute the material. The correct volume of Ribi adjuvant was then added to the antigen preparation, and the mixture was again vortexed for 1 minute. Any unused formulated material was discarded, and -any unused Ribi adjuvant was stored at 4 C and used to formulate booster injections. Animals were primed on day 1 and boosted on day 14. Animals were euthanized on day 17, when popliteal lymph nodes were .=excised post mortem.and returned to the lab for processing.

Generation of Hybridomas Hybridoma cell lines were created essentially as described by Kohler and Milstein (1975).
Lymphocytes derived from inununized animals were fused with a murine myeloma cell line (Sp2/0) by incubation with polyethylene glycol (PEG). Following fusion, cells were maintained in selective medium containing hypoxanthine, aminopterin and thymidine (HA.T
medium) that facilitates only the outgrowth of chimeric fused cells.
On the day before the fusion, the fusion partner (Sp2/Ox Agl4 cells in dividing stage with viability above 95%) was split at 1 X 105 viable cells/ml, 24 hours before the fusion. On the day of the fusion, the mice were sacrificed and the lymph nodes were excised and placed in a Petri dish containing pre-warmed room temperature DMEM supplemented with 10% fetal bovine serum (FBS). Using sterile n=ii.croscope slides, the lymph nodes were placed between the 2 frosty sides of the slides and crushed into a single cell suspension. The cell suspension was then transferred to a 15 ml tube and centrifuged for 1 minute at 1000 rpm. The supematant was removed by aspiration, and the cell pellet gently resuspended in 12 ml of serum-free DMEM, after which they were subjected to another round of centrifugation for 10 minutes at 1000 rpm.
The process was repeated twice more to ensure that the serum was completely removed. After washing, the cells were resuspended in 5 ml of senun-free DMEM and counted under the microscope.
The fusion partner was collected by spinning in a centrifuge for 10 minutes at 1000 rpm.
The cells were washed three times in serum-free DMEM, and finally resuspended in sesum-free DMEM and counted. The number of fusion partner cells were calculated based on the nurnber of lymph node cells. For every myeloma cell (fusion partner), 2 lymph nodes cells is needed (ratio 1:2 of myeloma to lyrnph node cells; e.g. for l Ox 1061ymph node cells, 5x 106 fusion partner cells are needed). The appropriate number of myeloma cells to the LN cells were added and the total volume of cells was adjusted to 25 ml using serum free DMEM, and 25 ml of 3%
dextran was then added to the cells. The mixture was spun for 10 minutes at 1000 rpm, and the supernatant aspirated as much as possible from the cell pellet. Once the lid was placed onto the tube containing the cells, the bottom of the tube was gently tapped the bottom of the tube to resuspend the cells and 1 ml of pre-warmed 50% (v/v) PEG was added to the tube. The agglutinated cells were,allowed to sit for I minute, after. which 20 ml of serum free DMEM, followed by 25 ml of 20% FBS, DMEM with 25 mM Hepes was added. The tube was inverted once to mix and then -centrifuged for 10 minutes at 1000 rpm. The media was aspirated and the cells were gently resuspended by tapping. HAT selection media was added such_that the cell suspension was either at 0.125 x 106 cells/ml or 0.0625 x 106 cells/ml. -One hundred* l of cells per well were added to a 96=wel1 flat bottom plate and incubated at 37 C with COZ at 8.5%_ After 2 days, the cells were fed with 100 l of fresh HAT selection media. Cells were checked for colony growth after *7.days.

Hybrido.ma Screening Once visible colonies were observed in the 96 well plates, 100 l of conditioned supematatit was harvested from each colony for screening by ELISA.
Supernatants were screened for the presence of detectable levels of antigen-specific IgG against both CDr-HSD and CDs-HSD extracts. Only colonies exhibiting a positive ELISA reaction against one of the two -extracts with at least a 2-fold difference were selected for expansion and further characterization.
Pancreas extract at a concentration of 25 g/ml to be tested was diluted in carbonate bicarbonate buffer (1 capsule of carbonate-bicarbonate was dissolved in 100 ml of deionized water). .Two extra wells for the positive control and two extra wells for the negative control of a 96-well plate were reserved. The plate was then covered using adhesive film and incubated at 4 C overnight.
The plate was washed once with 200 l of PBS/Tween. The well content was removed by flicking the plate into a sink, and then gently tapping the plate against absorbent paper to remove remaining liquid. Approximately 200 l of washing buffer (PBS/Tween) was added and subsequently discarded as previously described. The entire plate was then blocked for 1 hour at 37 C in 200 l of 5% powdered milk/PBS/Tween. The plate was then washed 3 times using PBS/Tween as previously described.

The fusion culture supernatant was diluted 1:1 in 0.5% milklPBS/Tween and each sample added to the wells (50 l; final volume is 100 l per well) with 50 l of anti-actin Ab (Sigma) at 20 g/ml to well containing 50 1 of buffer. Fifty l of buffer was added to the negative control well. The plate was covered and incubated overnight at 4 C. The plate was washed 3 times using PBS/Tween as previously described, and anti-HRP anti-mouse IgG in 0.5%
milk/PBS/Tween at 1:20000 (100 1) was added to each well. The plate was covered and incubated at 37 C for two hours.
- After incubation with secondary antibody; the plates were washed 4 to 5 times as previously described. On'the last wash, the washing buffer was left on the plate for a couple of = 10 minutes before discarding it. One hundred l of pre-warmed room temperature TMB (VWR;
stored in the dark) was added to each well while riminimizing the introduction of bubbles, until the color developed (20-30 minutes). The reaction was stopped by adding 50 g1 of 2M sulfuric acid. The plate'vvas read using a spectrophotometer at 450 nm.
Thirteen clones produced monoclonal antibodies (mAbs) that met the experimental criteria outlined above, 9 against CDs-HSD and 4 against CDr-HSD. The ELISA
data for these colonies is summarized in Table 5 and graphically represented in Figures 17A
and 17B. Table 8 shows ELISA screening data for monospecific CDr-HSD and CDs-HSD hybridomas.
Absolute -absorbance values, and fold difference at OD 450 nm is shown for each colony.
To verify primary screening data, some clones were retested during expansion to confirm the experimental observations from the initial screen.
Table 8 Primary Screen Confirmatory Screen Clone ID CDR-HSD CDS-HSD DiffeFold rence CDR-HSD CDS-HSD DiffeFold rence P1-5-1711 0.021 0.426 20.29 0.013 0.192 14.77 P1-14-A2 0.363 0.714 1.97 NT NT -P1-17-E4 0.042 0.398 9.48 NT NT -P1-18-C12 0.021 0.183 8.71 NT NT -P1-20-B7 0.065 0.192 2.95 0.025 0.110 4.40 P1-23-F7 0.039 0.912 23.38 0.046 0.547 11.89 P2-1-E8 0.001 0.139 139.00 0.019 0.252 13.26 P2-10-E3 0.007 0.249 35.57 0.017 0.153 9.00 P2-14-C6 0.006 0.353 58.8 0.054 0.143 2.65 P2-4-H5 0.214 0.058 3.69 0.217 0.065 3.34 P2-8-A3 0.184 0.095 1.94 0.227 0.065 3.49 P2-10-B8 0.101 0.055 1.84 0.12] 0.029 4.17 P2-13-A9 0.114 0.004 28.5 0.213 0.035 6.09 To derive monoclonal hybridoma lines, each colony was subcloned by limiting dilution.
The resulting clonal lines derived from each parent colony were rescreened and ranked by O.D.
450 nm to determine the best clones. The top 10 antibody secreting clones were expanded and archived in liquid nitrogen storage. Cells were couinted and:ensured that the viability was at least 80%. Cells were prepared in subcloning media containing 10% FBS and 10%
hybridoma cloning factor (bioVeris) in DMEM at 5 cells/ml (about 60 ml for 3 plates).
Another set of the same cells was prepared at a coricentration of -1.6 cells/ml (about 60 ml for 3 plates). Two hundred l of cells were plated per well in a 96 well round bottom plate. One set of 3 plates contained 1 cell/well, and another contained, on average, I cell every 3 wells. After 10 days, cells were visible, and the subclones were tested for specificity. Cells of interest were expanded in a 24 well plate in 10% FBS DMEM containing 5% of hybridoma cloning factor.
The composition of each n-iA.b was defined by determining-the class of heavy and light chains, as well as the molecular- weight, of each component. Isotyping was performed using the Immunopure monoclonal antibody isotyping kit I (Pierce) according to the manufacturer's instructions. The molecular weight of heavy and light chains was determined using the Experion automated electroph.oresis. system from Bio-Rad. The Experion system automatically performs the multiple steps of gel-based electrophoresis: separation, stairiing, destaining, band detection, imaging, and data analysis. The results of these analyses are shown in Table 9, which shows the physical characterization of CDr-HSD and CDs-HSD specific monoclonal antibodies.
Identification of both heavy and light chains was performed using the Immunopure monoclonal antibody isotyping kit I (Pierce), and molecular weights (in kD) were determined using the Experion automated electrophoresis system (Bio-Rad).
Table 9 Light chain Hea chain Whole IgG
Clone ID Subtype Mol.Wt. Subclass Mol.Wt. Mo1.Wt.
- -P1-5-FIi kappa - IgG2b Pl-14-A2 Kappa/ lambda - I G1 - -- -P1-17-E4 Kappa - IgGI
- -PI-18-C12 Kappa - IgG2b P1-20-B7 Kappa - - IgGl - -P1-23-F7 Kappa - IgG2b - -P2-1-E8 Kappa - IgGI - -- -P2-10-E3 Kappa - IgG2a - -P2-14-C6 Kappa - IgGI
P2-4-H5 Ka a ~ - IgG2b - -P2-8-A3 Kappa - I G2b -P2-10-B8 Kappa. - IgG2b - -P2-13-A9 kappa - IgGI
- -To determine the specific 'antigen for each clone, each rnAb was tested by Western Blotting to ascertain the molecular weight of the corresponding antigen. Data obtained from reactive clones is shown in Figures 18A-18C.
To purify the antigen specific for P240-B8-KA8, an immunoprecipitation was performed.
Specific antibody was bound to Protein G beads and used to pan for antigen from CDr-HSD
pancreatic extract containing 6 mg of total protein. In an Eppendorf tube, CDR-HSD pancreatic extract was centrifuged for 5 minutes at 13,000 rpm, and the deposit on the top of the extract was removed. Without removing any of the pellet, 6mg of extract was transferred to 3 clean centrifuge tubes and the volume adjusted I ml by addition of T-per buffer. To tube 1, 100 ~ig of purified P2-10-B8-KA8 was added to:the.diluted sample, 200 g of purified P2-10-B8-KA,8 was added to tube 2, and 300 g of purified P2-10-B8-KA.B was added to tube 3. The tubes were rotated at 4 C overnight.

Protein G beads slurry (1 ml) were centrifuged for 3 minutes at 500 x g in an Eppendorf centrifuge, and washed twice with pre-chilled T-per buffer by diluting the beads 1:1 with the buffer. The slurry (200 l) was transferred to each tube containing the antibody-antigen mixture.
A control tube was set up by preparing a tube with 200 l of slurry in I ml of T-Per buffer and 300 g of"antibody. The tubes were rotated at 4 C for 2 hours. Thereafter, the beads were washed twice using pre-chilled T-per buffer (centrifuged at 500 x g for 3 minutes) and the supematants retained. After one final wash in cold PBS, the supernatant was removed as much as possible and 100 l of 2X sample buffer (Pierce 5X loading buffer: 200 I
of loading buffer, 100 1 of reducing agent, complete with 200 l of water) was added. The samples were boiled for 5 minutes at 95 C and subsequently cooled on ice for 5 minutes. After spinning the sarnples for 3 minutes, each sample was loaded in an amount of 20 1 per lane on a 4-12% SDS-PAGE
rnini gel for electrophoresis.
Following precipitation, several.bands were visible on the gel after staining for total protein with Coomassie. A faint doublet band was observed in the molecular weight range of 70 to 8,0 kD (see Figure 19). The doublet was confirmed to be the bands of interest by probing a Western Blot prepared from a similar gel with the same mAb (data not shown).
The doublet bands were excised individually from the SDS-PAGE gel and submitted for identification by mass spectrometry. An positive identification of the lower band as calnexin was made.
Calnexin is a molecular chaperone associated with the endoplasmic reticulum.
Calnexin is a 90 kD integral protein of the endoplasmic reticulum (ER). It consists of a large (50 kD) N-terminal calcium-binding lumenal domain, a single transmembrane helix and a.
short (90 residues), acidic cytoplasmic tail. Calnexin belongs to a family of proteins known as "chaperones," which are characterized by their main function of assisting protein folding and quality control, ensuring that only properly folded and assembled proteiris proceed further along the secretory pathway. The function of calnexin is to retain unfolded or unassembled N-linked glycoproteins in the endoplasnuc reticuluin. Calnexiin binds only those N-glycoproteins that have GlcNAc2Man9Glc l oligosaccharides. Oligosaccharides with three sequential glucose residues are added to asparagine residues of the-nascent proteins in the ER.
The monoglucosylated oligosaccharides that are recognized by calnexin result from the trinvming of two glucose residues by the sequential- action of two glucosidases, I and II.
Glucosidase II can also remove the third and last glucose residue. If the glycoprotein is not properly folded, an .l5 enzynie called UGGT will add the glucose residue back onto the oligosaccharide -thus regenerating the glycoprotein ability to bind to calnexin. The glycoprotein chain which for some reason has difficulty folding up properly thus loiters:in the ER, risking the encounter with MNS 1 (a-mannosidase), which eventually sentences the underperforming glycoprotein to degradation by rernoving its mannose residue. ATP and Ca2+ are two of the cofactors involved in -substrate binding for calnexin. Figures 20A and 20B are screen shots depicting the read-out of the MS
spectrograms identifying the protein of interest as calnexin. .

Example 2: Microarray Analysis of Gene Expression in Tissues from Cohen Type 2 Diabetic Rats The microarray data were analyzed through Phase I and Phase II analyses. Phase I is based on the processed data from Gene Logic. Phase II corresponds to data analysis using GeneSpring GX. Additional criteria including statistics, signaling pathways and clustering were used for the analyses. =
The microarray results from Gene Logic (Phase I) that were derived from comparisons of pancreatic total RNA of Cohen Type 2 Diabetes rats (CDs-HSD, CDr-HSD) were analyzed using MAS5.0 software from Affymetrix, Inc. The global gene expression analysis showed that there were 1178 genes upregulated in CDr-HSD and 803 genes were downregulated in compared to CDs-HSD. Many of these transcripts are involved in several signaling pathways related to Type 2 Diabtes such as insulin signaling, beta-cell dysfunction and lipid and glucose metabolisms.
Also, several serpin fan-iily members (serine proteinase inhibitors) are expressed differently in the two models.
Table 10 provides a summary of the data derived from Gene Logic, wherein changes greater than 3-fold were observed.

Signaling Pathways Upregulated genes Downregulated genes CDR-HS vs. CDS- CDR-HS vs. CDS-HS
HS
sulin signaling 39 1 (3 cell dysfunction (a o tosis, survival) 17 6 flarrunation and immune system 5. _ 92 Mitochondrial dysfunction and reactive 0 8 xygen species i id and glucose metabolisms 17 . 13 roteinase and proteinase inhibitors 8 17 Aiiiino acid, nucleic acid transporters aind 13 9 etabolisms otassium channels 3 6 PR and Golgi body related genes 8 8 Other unclassified genes 1028 603 otal 1178 803 Phase II data analysis was performed using G.eneSpring GX, which used normalized data (ratio = transcript signal/control signal) to improve cross-chip comparison.
GeneSpring GX
allows for gene lists to be filtered according to genes exhibiting a 2-fold or 3-fold change in the expression levels. GeneSpring GX also comprises statistical algorithms, such as ANOVA, Post-Hoc Test, and Cross-Gene Error Modeling, as well as gene clustering algorithms like Gene Tree, K-mean clustering, and Self-Organizing Map (SOM) clustering. GeneSpring GX
also has the ability to integrate with pathways that are published in the art, such as the Kyoto Encyclopedia of Genes and Genomes ("KEGG pathways") and Gen Map Annotator and Pathway Profiler (GenMA-PP).
The microarray results analyzed by GeneSpring GX show that among the transcripts with changes higher than three fold in the two groups, 137 transcripts have a p-value of less than 0.05.
These genes are involved in several signaling pathways such as the insulin signaling pathway, serpin protein family, basic metabolism, pancreas function and inflammation.
Figure 21 shows a scatter plot of differentially expressed genes. The 137 transcripts whose levels show a change of three-fold or higher are shown in Figure 22B and are also grouped in Tables 11 and 12.

Table 11 Upregulated genes Tota1= 101 Transcripts) Common UniGene Descri tion Reg3a Rn.11222 Regenerating islet-derived 3 alpha LOC680945 Rn.1414 Similar to stromal cell-derived factor 2-like I
Pa Rn.9727 Pancreatitis-associated protein Ptfl a Rn.10536 Pancreas specific transcription factor, 1 a Matla Rn.10418 Methionine adenosyltransferase I, alpha Nu r=1 Rn.11182 Nuclearprotein 1 Rn.128013 unknown cDNA
Chacl redicted Rn.23367 ChaC, cation transport regulator-like 1 (E. coli) ( redicted ' Solute carrier family 7(cationic amino acid transporter, y+
Slc7a3 Rn.9804 system), member 3 LOC312273 Rn.I3006 T sin V-A
Rn.47821 Transcribed locus Pt er3 Rn. 10361 Prostaglan din E receptor 3 (subtype EP3) RGD1562451 redicted Rn.199400 - Similar to Pab c4 redicted protein ( redicted RGD15~6242 redicted Rn.24858 Similar to RIKEN cDNA 1500009M05 (predicted) C 2d26 Rn.91355 Cytochrome P450, family 2, subfamily d, polypeptide 26 Rn. 17900 similar to aldehyde dehydro enase 1 family, member L2 LOC286960 Rn.10387 Pre rot sino en IV
Gls2 Rn.10202 Glutaminase 2 (liver, mitochondrial Nme2 Rn.927 Expressed in non-metastatic cells 2 Rn.165714 Transcribed locus P2rx1 R.n.91176 Purinergic receptor P2X, li and- ated ion channel, I
Pdk4 Rn.30070 Pyruvate dehydrogenase kinase, isoenzyrne 4 Amyl Rn.1 16361 Amylase 1, salivary Cbs Rn.87853 Cystathionine beta synthase Mtel Rn.37524 Mitochondrial acyl-CoA thioesterase I
Spink] Rn.9767 Serine protease inhibitor, Kazal type 1 Glycine amidinotransferase (L-arginine:glycine Gatm Rn.17661 amidinotransferase) Transmembrane emp24 protein transport domain Tmed6 redicted Rn.19837 containing 6 (redicted Tff2 Rn.34367 Trefoil factor 2 s asmol 'c protein 1) Hsd17b]3 Rn.25104 Hydroxysteroid (17-beta) dehydrogenase 13 Rn.11766 imilar to LRRGT00012 [Rattus norvegicus]
Gnmt Rn.11142 Glycine N-methyltransferase Pah R.n.1652 Phenylalanine hydroxylase Serpini2 Rn.54500 serine (or cysteine) proteinase inhibitor, clade 1, member 2 RGD1309615 Rn.167687 unknown cDNA
LOC691307 Rn.79735 Similar to leucine rich repeat containing 39 isoform 2 Eprs = Rn.21240 Glutamyl-prolyl-tRNA synthetase Phosphoenolpyruvate carboxykinase 2 (mitochondrial) Pck2 redicted Rn.35508 (predicted) Chromodomain helicase DNA binding protein 2 Chd2 redicted Rn.162437 ( redicted) Common UniGene Descri tion Rn.53085 Transcribed locus Rn.12530 Transcribed locus NIPK Rn.22325 tribbles homolog 3 (Drosophila) S1c30a2 Rn.111=35 Solute carrier family 30 (zinc transporter), member 2 Serine (or cysteine) peptidase inhibitor, clade A, member Se inal0 Rn.10502 10 Cfi Rn.7424 Complement factor I
.=Cckar Rn.10184 Cholecystokinin A receptor LOC689755 Rn.151728 Hypothetical protein LOC689755 Bhlhb8 Rn.9897 Basic helix-loo -helix domain containing, class B, 8 'Anpep Rn.11132 Alanyl (membrane) aminopeptidase.
Asns Rn.11172 Asparagine synthetase Solute carrier family 7 (cationic amino acid transporter, y+
Slc7a5 Rn.32261= system), member 5 - =
Us 43 redicted Rn. 12678 Ubiquitin specific proiease 43 (predicted) =
Csnklal Rn.23810 Casein kinase 1, alpha 1 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) Pck2 redicted Rn.35508 (predicted) S inkl Rn.9767 Setine protease inhibitor, Kazal type 1 Cml2 = . Rn.160578 Camello-like 2 Pab c4 Rn.199602 Transcribed locus Gjb2 Rn.198991 Gap 'unction membrane channel protein beta 2 . Ngfg Rn.11331 Nerve growth factor, gamma Clca2 redicted Rn.48629 Transcribed locus RGD1565381 redicted = Rn.16083 Similar to RIKEN cDNA 1810033M07 (predicted) Qscn6 Rn.44920 Quiescin Q6 Cldn10 redicted Rn.99994 Claudin 10 (predicted) Spink3 Rn. 144683 Serine protease inhibitor, Kazal type 3 Similar to NipSnap2 protein (Glioblastoma amplified LOC498174 Rn.163210 sequence) similar to Methionine-tRNA synthetase (Rattus Rn. 140163 norvegicus) Cyr61 Rn.22129 Cysteine rich protein 61 RGD1307736 Rn.162140 Similar to Hypothetical protein KIAA0152 Ddit3 Rn. 11183 DNA-damage inducible transcript 3 Regl Rn.11332 Regenerating islet-derived 1 E rs Rn.21240 Glutam 1- rolyl-tRNA synthetase NIPK Rn.22325 =cDNA clone RPCAG66 3' end, mRNA sequence.
Eif4b Rn.95954 Eukaryotic translation initiation factor 4B
Spinkl Rn.9767 Serine protease inhibitor, Kazal type I
Rnase4 Rn.1742 Ribonuclease, RNase A family 4 Ceb g Rn.10332 CCAAT/enhancer binding protein C/EBP), gamma siat7D Rn.195322 AI ha-2,6-sial ltransferase ST6GalNAc IV
He udl Rn.4028 Homocysteine-inducible, ubiguitin-like domain member I
unknown rat cDNA
Glycine C-acetyltransferase (2-amino-3-ketobutyrate-Gcat Rn.43940 coenzyme A ligase) RGD1562860 redicted Rn.75246 Similar to RIKEN cDNA 2310045A20 redicted) Hs a9a redicted Rn.7535 Heat shock 70kD protein 9A ( redicted Dbt Rn.198610 Dihydroli oamide branched chain transacylase E2 Common UniGene Description Bspry Rn.53996 B-box and SPRY domain containing Futl Rn.11382 Fucosyltransferase 1 Rp13 Rn.107726 Ribosomal protein L3 similar to NP_083620.1 acylphosphatase 2, muscle type Rn.22481 [Mus musculus]
unknow rat cDNA
Vldlr Rn.9975 Very low density lipoprotein receptor RGD1311937 redicted Rn.33652 Similar to hypothetical protein MGC 17299 ( redicted RGD1563144 redicted Rn. 14702 Similar to EMeg32 protein ( redicte.d) Rn.43268 Transcribed locus re-mtHSP70 Rn.7535 70 kD heat shock protein precursor;
Ddah1 Rn.7398 Dimethylarginine dimethylaminohydrolase I
RGD1307_736 Rn.162=140 Similar to Hypothetical protein KIAA0152 RAMP4 Rn.2119 ' Ribosome associated menibrane protein 4 Pt er3 ._.' Rn.10361 Prosta landin E reoe tor 3 (subte EP3) Rn.169405 =.. Transcribed locus CCbel redicfed Rn.199045 . Collagen and calcium binding EGF domains 1 (predicted) Dna'c3 Rn. 162234 DnaJ (H0) homolog, subfamily C, member 3 Mtae2dl = Rn.43919 - Membrane targeting (tandem) C2 domain containing 1 Table 12: Downregulated enes (Total = 36 transcripts) Common UniGene Description RGD1563461_predicted .Rn.199308 . Transcribed locus Gimap4 Rn.198155. GTPase, IMAP family member 4 S100b Rn.8937 S100 protein, beta polypeptide KIf2_predicted Rn.92653 Kruppel-like factor 2 (lung) (predicted) RGD1309561_predicted Rn.102005 Similar to hypothetical protein FLJ31951 (predicted) NAP22 Rn.163581 Transcribed locus Sfrs3_predicted Rn.9002 Splicing factor, arginine/serine-rich 3(SRp20) ( redicted) Rn.6731 Transcribed locus Cd53 Rn.31988 CD53 antigen RGD1561419_predicted Rn.131539 Similar to RIKEN cDNA 6030405P05 gene (predicted) I12rg Rn. 14508 Interleukin 2 receptor, gamma LOC361346 Rn.31250 Similar to chromosome 18 open reading frame 54 Cd38 Rn.11414 CD38 antigen KIf2_predicted Rn.92653 Kruppel-like factor 2(lung) (predicted) Plac8_predicted Rn.2649 Placenta-specific 8 (predicted) LOC498335 Rn.6917 Similar to Small inducible cytokine B13 precursor (CXCL13) Igfbp3 Rn.26369 Insulin-like growth factor binding protein 3 Ptprc Rn.90166 Protein tyrosine phosphatase, receptor type, C
RTI-Aw2 Rn.40130 RTI class Ib, locus Aw2 =
Rac2 Rn.2863 RAS-related C3 botulinum substrate 2 Rn.9461 Transcribed locus Fos Rn.103750 FBJ murine osteosarcoma viral oncogene homolog Arhgdib Rn.15842 Rho, GDP dissociation inhibitor (GDI) beta Sgnel Rn.6173 = Secretory granule neuroendocrine protein I
Lck mapped Rn.22791 Lymphocyte protein tyrosine kinase (mapped) Common UniGene Description Fcgr2b Rn.33323 Fc receptor, IgG, low affinity IIb SifnB Rn.137139 Schlafen 8 Rab8b Rn. 10995 RA.B8B, member RAS oncogene family Rn.4287 unknown cDNA
RGD 1306939 Rn.95357 Similar to mKIAA0386 protein Tnfrsf26_aredicted Rn. [62508 Tumor necrosis factor receptor superfamily, member 26 redicted Ythdf2predicted Rn.21737 YTH domain family 2 (predicted) RGD1359202 Rn.10956 Similar to immunoglobulin heavy chain 6(Igh-6) RGD1562855~redicted Rn. ] 17926 Similar to Ig kappa chain (predicted) Igha_mapped Rn. 109625 Immtinbglobulin heavy chain (alpha polypeptide) ma ped) Ccl2lb Rn.39658 Chemokine (C-C motif) ligand 21b (serine) Gene Tree gene clustering analysis, represented in Figure 22A, shows the 12,729 genes that are present in all six samples. As discussed.above, 820 genes showed 2-fold changes in expression, whi(e 13.7 genes showed 3-fold changes in expressi4n., aad a Gene Tree representation 'is shown in Figure 22B.. Of the 137 genes that showed 3-fold changes, K-mean clustering analysis further divided these 137 genes into 5 sets, based on the.
greatest similarities between the genes within the sets (Figure 21 C). These 5 sets are desigriated "Up-l ", "Up-2", "Up-3", "Up-4", and "Up-5" and are summarized in Tables 13-17 below.
Table 13: Up-I
--=., -10 [Total genes:91 ! .,= ( Fold ..._..___._..
_.._._...___.....~._._..___.,..._..__.____._.._..__....________...-_----_._._._......._...____...__. ..__ _._...___...- =---_._..__.._...._._.~
Common = Description ( Changes Reg3a Regenerating islet-derived 3 alpha = 75.08 LOC680945, Similar to stromal cellilerived factor 2-like 1 32.31 Pap Pancreatitis-associated protein 19.53 PtP9a Pancreasspecifictranscriptionlactor, 1a 11.59 Mat1a Methionine adenosyltransferase 1, alpha 8.67 Nupri Nuclear protein 1 7.53 unknown cDNA 7.52 Chacl_predicted ChaC, cation transport regulator-like 1(E. coii) (predicted) 7.41 Slc7a3 Solute canier famity 7 (cationic amino acid transporter, y+ system), member 3 6.68 L0C312273 Trypsin V-A = 6.38 Transcribed locus 6.08 Ptger3 Prostaglandin E receptor 3 (subtype EP3) 6.01 RGD1562451_predicte Similar to Pabpc4_predicted protein (predicted) 5.88 RGD1566242__predict Similar to RIKEN cDNA 1500009M05 (predicted) 5.62 Cyp2d26 Cytochrome P450, famity 2, subfamily d, polypeptide 26 5.59 similar to aidehyde dehydrogenase 1 family, member L2 [Canis familiaris] 5.37 LOC286960 Preprotrypsinogen IV 5.19 GIs2 Glutaminase 2(lker, mitochondrial) 5.10 Table 14: Up-2 iTotal genes: 91 I I Fold Common Description Changes Transcribed locus 4.92 P2rxl Purinergic receptor P2)~ ligand-gated ion channel, 1 4.85 Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 4.72 Amyl Amylase 1, salivary 4.70 Cbs Cystathionine beta synthase 4.67 Mtel Mitochondrial acyl-CoA thioesterase 1 4.49 Spink1 Serine protease inhibitor, Kazal type 1 4.43 Gatm Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 4.40 Tmed6_predicted Transmembrane emp24 protein transport domain containing 6 (predicted) 4.38 TfR Trefoil factor 2(spasmolytic protein 1) 4.36 Hsdl7bl3 Hydroxysteroid (17-beta) dehydrogenase 13 4.34 similar to LRRGT00012 [Rattus nomgicus] 4.30 Gnmt Glycine N-methyltransfeidse = 4.30 Pah Phenylatanine hydroxylase 4.29 Serpini2 serine (or cysteine) proteinase inhibitor, clade I, member 2 4.28 RGD1309615 = unknown cDNA 4.16 LOC691307 Similar to leucine rich repeat containing 39 isoform 2 4.12 Eprs Glutamyl-prolyi-tRNA synthetase = = = 4.03 PCk2_predicted Phosphoenolpyruvate carboxykinase 2(mitochondrial) (predicted) 4.01 Table 15: Up-3 Total genes: 91 Fold Common Description = Changes I 5 Transcribed locus == 3.97 Transcribed locus 3.96 SIc3Oa2 Solute canier family 30 (zinc transporter), member 2 3.77 SerpinalO Serine (or cysteine) peptidase inhibitor, clade A, mem&er 10 3.77 Cfi Complement factor I = 3.69 Cckar Cholecystokinin A receptor 3.68 LOC689755 Hypothetical protein LOC689755 3_68 Bhlhb8 Basic helix-loop-helix domain containing, class B, 8 = 3.66 Anpep Alanyl (membrane) aminopeptidase 3.65 Asns Asparagine synthetase 3.65 Usp43_predicted Ubiquitin specific protease 43 (predicted) 3.62 SIc7a5 Solute carrierfamily 7 (cationic amino acid transporter, y+ system), member 5 3.62=
Csnklal Casein kinase 1, alpha 1 3.58 Cm12 Camello-like 2 3.51 Pabpc4 Transcribed locus 3.50 Gjb2 Gap junction membrane channel protein beta 2 3.49 Ngfg Nem growth factor, gamma 3.47 CIca2_predicted Transcribed locus 3=46 RGD1565381_predict Similar to RIKEN cDNA 1810033M07 (predicted) 3.42 Qscn6 Quiescin Q6 = 3.41 Table 16: Up-4 Total genes: 91 Fold ;
Common Description Changes CidnlO_predicted Claudin 10 (predicted) 3.40 Spink3 Serine protease inhibitor, Kazal type 3 3.38 LOC498174 Similar to NipSnap2 protein (Glioblastoma amplified sequence) 3.36 similar to Methionine-tRNA synthetase [Rattus norvegicus] 3.35 Cyr61 Cysteine rich protein 61 3.33 RGD1307736 Similar to Hypothetical protein KIAA0152 3.32 Ddit3 DNA-damage inducible transcript 3 3.32 Regi Regenerating islet-derned 1-= =- . 3.22 NIPK unicnowp cDNA ' . . 3.19 Eif4b Eukaryotic transiation initiation factor 4B 3.17 Rnase4 Ribonuclease, RNase A famil~ 4 3_16 Cebpg CCAAT/enhancer binding protein (C/EBP), gamma.. 3.16 siat7D Alpha-2,6-siaiyltransferase STG.GaIN/ac IV' 3.15.
Herpud1 Homocysteine-inducibie,.,=ubiquitin-iike domain member 1 3.15 Gcat Glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase) 3.13 RGD1562860_predicte Similar to RIKEN cDNA 2310045A20 (predicted) 3.11 Hspa9a_predicted Heat shock 7OkDa protein9A (predicted) ' 3.10 Dbt Dihydrolipoamide branched. chain transacylase E2 3.10 Bspry B-box and SPRY domain containing 3.10 Table 17: Up-5 ;Totai genes: 91 Fold Common Description Changes Fut1 Fucosyitransferase 1 _ .3.09 Rpl3 = Ribosomat protein L3 = = 3:08 strongty simifar to iYP 083620.R acyiphosphatase 2, muscle type [Mus muscu 3.08 Vidlr = Very low density lipoprotein receptor 3.07 RGD1311937_predicte Similar to hypothetical protein MGC17299 (predicted) 3.04 RGD1563144_predicte Similar to EMeg32 protein (predicted) 3.04 Transcribed iocus 3.04 Ddahl Dimethylarginine dimethylaminohydrolase 1 3.03 RAMP4 Ribosome associated membrane protein 4 3.01 . Transcribed locus.. 3.01 Gcbe1_predicted Collagen and calcium binding EGF domains 1(predicted) 3.01 Dnajc3 DnaJ (Hsp4O) homoiog, subfamily C, member 3 3.00 Mtac2dl Membrane targeting (tandem) C2 domain containing 1 3.00 Two additional sets, named "Down-1" and "Down-2" represent genes that were found by GeneSpring GX analysis to be downregulated in the Cohen diabetic rat samples.
The following Tables 18 and 19 summarize the results obtained in the "Down-1" and "Down-2"
sets-Table 18: Down-1 __.___-_-_ __-____.__._.___._..----.___..---... _---__..__-,-.___._ ~., ~Total genes: 35 genes ( I Fold Common Description Change Ccl2lb Chemokine (C-C motif) ligand 21b (serine) 11.33 Igha_mapped Immunoglobulin heavy chain (alpha polypeptide) (mapped) 7.63 RGD1562855_predicted Similar to Ig kappa chain (predicted) .4.98 RGD1359202 Similar to immunoglobulin heavy chain 6(lgh-6) 4.78 Ythdt2_predicted YTH domain family 2 (predicted) = 4.63 Tnfrst26_predicted Tumor necrosis factor receptor superfamily, member 26 (predicted) 4.37 RGD1306939 Similar to mKIAA0386 protein 4.33 unknown cDNA 4.24 Rab8b RAB8B, member RAS oncogene family = 4.10 51fi8 Schlafen 8 3.91 Fcgr2b Fc receptor, IgG, low affinity llb 3.79 Lck_mapped Lymphocyte protein tyrosine kinase (mapped), 3.66 Sgnel Secretory granule neuroehdo'6rine protein 1 = 3.56 Fos FBJ murine osteosarcoma viral bncogene homolog = 3.55 Arhgdib Rho, GDP dissociation inhibitor:(GDI) beta 3.55 Transcribed locus = 3.51 Rac2 RAS-related C3 botulinum substtate 2 3.42 Table 19: Down-2 ~_.....---..._.._.__. - __..___.._ .............._....._.__._...._...... .... ...---...... ....__--.
Motal genes: 35 genes Fold, ;
Common Description = = -=== = Change RT1 Aw2 RTI class lb, locus Aw2- = 3.39 Ptprc Protein tyrosine phosphatase, receptor type, C 3.39 lgtbp3 Insulin-like growth factor binding=protein 3 3.37 LOC498335 Similar to Small inducible cytokine B13 precursor (CXCL13) 3.27 PlacB_predicted Placenta-specific 8 (Predicted) 3.25 Cd38 CD38 antigen " 3.24 LOC361346 Similar to chromosome 18 open reading frame 54 3.24 RGD1561419_predicted Similar to RIKEN cDNA 6030405P05 gene (predicted) 3.19 112rg Interleukin 2 receptor, gamma (setiere' combined immunodeficiency 3.19 Cd53 = CD53 antigen 3.18 Transcribed locus . 3.16 Sfrs3_predicted Splicing factor, arginine/serine-rich 3(SRp20) (predicted) 3.15 RGD1309561_predicted Similar to hypothetical protein FLJ31951 (predicted) 3.13 NAP22 Transcribed locus 3.13 KIfi2_predicted Kruppel-like factor 2 (lung) (predicted) 3.11 S100b S100 protein, beta polypeptide 3.08 Gimap4 GTPase, IMAP family member 4 3.07 RGD1 563461 _predicted Transcribed locus 3.07 Finally, gene expression analyses obtained by microarray were confirmed using quantitative RT-PCR according to standard methods. The table below provides a summary of the genes of interest identified by microarray analysis and whose fold changes in expression .were verified using Q-RT-PCR.
Table 20: Quantitative RT-PCR Analysis on Selected Genes Downreguiated fABI, S. Common Genbank UniGene t)escriptlon Foid Chainge Cci21b BI282920 Rn.39658 Chemokine (C-C moti$ ligand 21b (serine) 11.33 250 TnfisP26_predicted BE098317 Rn.162508 Tumor necrosis factor receptor superfamily, member 26 (predicted) 4.37 250~
Igfbp3 NM 012588 Rn.26369 Insulin-Ilke growth factor binding protein 3 .37 150 112rg A1178808 Rn.14508 Interleukin 2 receptor, gamma sewre combined immunodeficiency) 3.19 V 250}
L ~_.__._._._ ____. {_._-___.._--_=_- ... ._...__...._._...._.._..
_._..____.__.__.....:-__.__._._ .__.._...._.. _ ___._.__..__......__---- ^-=---+
Upregulated Common Genbank UniGene Description Fold Change Reg3a L10229 Rn.11222 Regenerating Isiet-derfred 3 alpha == 75.08 -~ 250't LOC680945 BI275923 Rn.1414 Similar to stromal cell-derimed factor 2-like 1 32.31 - 25~I
Ptffa NM053964 Rn.10536 Pancreas s ific transctiption factor, 1a 11.59 LOC312273 A1178581 Rn.13006 Trypsin V-A 6.38 = 250.
LOC286960 = X15679 Rn.10387 Preprotrypsinogen IV 5.19 _ 25~i S inkl NM_012674 Rn.9767 Serine protease inhibitor, Kazal type 1" 4.43 150;
Serp1n12= = NM 133612 Rn.54500 serine (orcysteine) proteinase inhibilor; clade 1; member 2 4.28 250i Serpinal0 NM;133617 Rn.10502 Serine'(or cysteine) peptidase Inhibitor, clade.A, member 10 3.77 25D~
Spink3 M27883 Rn.144663 Serine protease inhibitor, Kaz.al type 3= :' _ :,'=
,.. 3.38 150; .
Reg1 NM_012641 Rn.11332 Regenerating istet-deriued 1 ~ 3.22 50 Eif4b B1278814 Rn.95954 = Eukaryotic lranslation initiation Eactor463.17 250I;
Rpt BG057530 Rn.107726 Ribosomal protein L3 3.08 =2501 .
RAMP4= A1103695 Rn.2119 Ribosome associated membrane protein 4 3.01 2501 ..
, ... .I . . ._. . .
__.__ _.......-..__...___..._._.:.__..__.._..._..__..:....'..__...--.
.....__....._......._.._....__......- -_...__._..,..-.---=
._.t__..._.ont_ __.ls . 14352338E __ :. _ __... ..... ..__._ _._..-_ GAPOH 50~
~Racro _ _ !
.. _ ---_...__...__..._._.._ .........._.__.. _.-.__. .. ..... . .... ._.... _ -........_....... __........._....._- !:.._.
...,~.__. ..... ....._ .
14352340E +AGTIN, BETA _...._._=-=---_ r .- ._. _..-......._..._... _...__....-...... _.-__....._.. .._..__.._.__.-..
__......._ ~ _.._.

The protein encoded by the CD53 gene is a member of the transmembrane 4 superfa.m'ily, also known as the tetraspanin family. Most of these members.are cell-surface proteins that are=.
characterized by the presence of four hydrophobic domains. The proteins mediate signal =transduction events that play a role in the regulation of cell development, activation, growth and motility_ This encoded protein is a cell surface glycoprotein that is known to complex with integriiis. It contributes to the transduction of CD2-generated signals in T
cells and natural killer cells and has been suggested to play a role in growth regulation. Familial deficiency of this gene has been linked to an immunodeficiency associated with recurrent infectious diseases caused by bacteria, fungi and viriuses. Alternative splicing results in multiple transcript variants encoding the same protein. CD.38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling-It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description.is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.
Other aspects, advantages, and modifications are within the ambit of the following claims. -

Claims (80)

1. A method of diagnosing or identifying type 2 Diabetes or a pre-diabetic condition in a subject, comprising a. measuring an effective amount of one or more DBMARKERS or a metabolite thereof in a sample from the subject; and b. comparing the amount to a reference value, wherein an increase or decrease in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from the type 2 Diabetes or the pre-diabetic condition.

2. The method of claim 1, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

3. The method of claim 1, wherein the decrease is at least 10% greater than the reference value.

4. The method of claim 1, wherein the increase is at least 10% greater than the reference value.

5. The method according to claim 1, wherein the sample is urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.

6. The method of claim 1, wherein the DBMARKER is detected electrophoretically, immunochemically, by proteomics technology, or by genomic analysis.

7. The method of claim 6 wherein the immunochemical detection comprises radio-immunoassay, immunoprecipitation, immunoblotting, immunofluorescence assay or enzyme-linked immunosorbent assay.

8. The method of claim 6, wherein the proteomics technology comprises SELDI, MALDI, LC/MS, tandem LC/MS/MS, protein/peptide arrays, or antibody arrays.

9. The method of claim 6, wherein the genomic analysis comprises polymerase chain reaction (PCR), real-time PCR, microarray analysis, Northern blotting, or Southern blotting.

10. The method according to claim 1, wherein the subject has not been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition.

11. The method according to claim 1, wherein the subject has been previously diagnosed as having type 2 Diabetes or a pre-diabetic condition.

12. The method according to claim 1, wherein the subject is asymptomatic for the type 2 Diabetes or the pre-diabetic condition.

13. A method for monitoring the progression of type 2 Diabetes or a pre-diabetic condition in a subject, comprising a. detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time;

b. detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time; and c. comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.

14. The method of claim 13, wherein the subject has previously been treated for the type 2 Diabetes or the pre-diabetic condition.

15. The method of claim 13, wherein the first sample is taken from the subject prior to being treated for the type 2 Diabetes or the pre-diabetic condition.

16. The method of claim 13, wherein the second sample is taken from the subject after being treated for the type 2 Diabetes or the pre-diabetic condition.

17. The method of any one of claims 14-16, wherein the treatment for the type 2 Diabetes or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.

18. The method of claim 13, wherein the progression is additionally monitored by detecting changes in body mass index (BMI), insulin levels, blood glucose levels, HDL
levels, systolic and/or diastolic blood pressure, or combinations thereof.

19. The method of claim 13, wherein the sample is urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.

20. The method of claim 13, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

21. A method of monitoring the effectiveness of a treatment regimen for type 2 Diabetes or a pre-diabetic condition in a subject comprising:

a. detecting an effective amount of one or more DBMARKERS in a first sample from the subject prior to treatment of the type 2 Diabetes or the pre-diabetic condition;

b. detecting an effective amount of one or more DBMARKERS in a second sample from the subject after treatment of the type 2 Diabetes or the pre-diabetic condition; and c. comparing the amount of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.

22. The method of claim 21, wherein the treatment regimen for the type 2 Diabetes or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.

23. The method of claim 21, wherein the effectiveness is additionally monitored by detecting changes in body mass index (BMI), insulin levels, blood glucose levels, HDL
levels, systolic and/or diastolic blood pressure, or combinations thereof.

24. The method of claim 23, wherein changes in blood glucose levels are detected by oral glucose tolerance test.

25. The method of claim 21, wherein the sample is urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.

26. The method of claim 21, wherein the subject has previously been treated for the type 2 Diabetes or the pre-diabetic condition.

27. The method of claim 21, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

28. A method of treating a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition comprising:

a. detecting an effective amount of one or more DBMARKERS or metabolites thereof present in a first sample from the subject at a first period of time;
and b. treating the subject with one or more diabetes-modulating agents until the amounts of the one or more DBMARKERS or metabolites thereof return to a reference value measured in one or more subjects at low risk for developing type 2 Diabetes or a pre-diabetic condition, or a reference value measured in one or more subjects who show improvements in Diabetes risk factors as a result of treatment with the one or more diabetes-modulating agents.

29. The method of claim 28, wherein the one or more diabetes-modulating agents comprise sulfonylureas, biguanides, insulin, insulin analogs, peroxisome proliferator-activated receptor-.gamma. (PPAR-.gamma.) agonists, dual-acting PPAR agonists, insulin secretagogues, analogs of glucagon-like peptide-1 (GLP-1), inhibitors of dipeptidyl peptidase IV, pancreatic lipase inhibitors, .alpha.-glucosidase inhibitors, or combinations thereof.

30. The method of claim 28, wherein the improvements in Diabetes risk factors as a result of treatment with one or more diabetes-modulating agents comprise a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.

31. A method of selecting a treatment regimen for a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition, comprising:

a. detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time;

b. detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time; and c. comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.

32. The method of claim 31, wherein the subject is suffering from type 2 Diabetes or a pre-diabetic condition.

33. The method of claim 31, wherein the subject has previously been treated for type 2 Diabetes or a pre-diabetic condition.

34. The method of claim 31, wherein the subject has not been previously diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

35. The method of claim 31, wherein the first sample is taken from the subject prior to being treated for type 2 Diabetes or a pre-diabetic condition.

36. The method of claim 31, wherein the second sample is taken from the subject after being treated for type 2 Diabetes or a pre-diabetic condition.

37. The method of claim 31, wherein the treatment for type 2 Diabetes or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.

38. The method of claim 31, wherein the reference value is derived from one or more subjects who show an improvement in Diabetes risk factors as a result of one or more treatments for type 2 Diabetes or the pre-diabetic condition.

39. The method of claim 38, wherein the improvement in Diabetes risk factors comprises a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.

40. The method of claim 39, wherein the reduction in blood glucose levels is measured by oral glucose tolerance test.

41. A method of evaluating changes in the risk of developing type 2 Diabetes or a pre-diabetic condition in a subject, comprising:

a. detecting an effective amount of one or more DBMARKERS in a first sample from the subject at a first period of time;

b. detecting an effective amount of one or more DBMARKERS in a second sample from the subject at a second period of time; and c. comparing the amounts of the one or more DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.

42. The method of claim 41, wherein the subject is suffering from type 2 Diabetes or a pre-diabetic condition.

43. The method of claim 41, wherein the subject has been previously treated for type 2 Diabetes or a pre-diabetic condition.

44. The method of claim 41, wherein the subject has not been previously diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

45. The method of claim 41, wherein the subject is asymptomatic for type 2 Diabetes or a pre-diabetic condition.

46. The method of claim 41, wherein the first sample is taken from the subject prior to being treated for type 2 Diabetes or a pre-diabetic condition.

47. The method of claim 41, wherein the second sample is taken from the subject after being treated for the pre-diabetic condition.

48. The method of claim 41, wherein the treatment for type 2 Diabetes or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.

49. The method of claim 41, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a pre-diabetic condition.

50. A method of identifying one or more complications related to type 2 Diabetes in a subject, comprising:

a. measuring an effective amount of one or more DBMARKERS or a metabolite thereof in a sample from the subject;. and b. comparing the amount to a reference-value, wherein an increase or decrease in the amount of the one or more DBMARKERS relative to the reference value indicates that the subject suffers from or is at risk for developing complications related to type 2 Diabetes.

51. The method of claim 50, wherein the complications comprise retinopathy, blindness, memory loss, nephropathy, renal failure, cardiovascular disease, neuropathy, autonomic dysfunction, hyperglycemic hyperosmolar coma, or combinations thereof.

52. The method of claim 50, wherein the reference value comprises an index value, a value derived from one or more diabetes risk-prediction algorithms or computed indices, a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or a value derived from a subject previously identified as having one or more complications related to type 2 Diabetes.

53. The method of claim 50, wherein the decrease is at least 10% greater than the reference value.

54. The method of claim 50, wherein the increase is at least 10% greater than the reference value.

55. The method of claim 50, wherein the sample is urine, serum, blood plasma, blood cells, endothelial cells, tissue biopsies, pancreatic juice, ascites fluid, bone marrow, interstitial fluid, tears, sputum, or saliva.

56. The method of claim 50, wherein the DBMARKER is detected electrophoretically, immunochemically, by proteomics technology, or by genomic analysis.

57. The method of claim 56, wherein the immunochemical detection comprises radioimmunoassay, immunoprecipitation, immunoblotting, immunofluorescence assay, or enzyme-linked immunosorbent assay.

58. The method of claim 56, wherein the proteomics technology comprises SELDI, MALDI, LC/MS, tandem LC/MS/MS, protein/peptide arrays, or antibody arrays.

59. The method of claim 56, wherein the genomic analysis comprises polymerase chain reaction (PCR), real-time PCR, microarray analysis, Northern blotting, or Southern blotting.

60. The method of claim 50, wherein the subject has not been previously identified as having type 2 Diabetes.

61. The method of claim 50, wherein the subject has been previously identified as having type 2 Diabetes.

62. The method of claim 50, wherein the subject has not been previously identified as having one or more complications related to type 2 Diabetes.

63. The method of claim 50, wherein the subject has been previously identified as having one or more complications related to type 2 Diabetes.

64. A Type 2 Diabetes reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS detected in one or more subjects who are not diagnosed with or identified as suffering from type 2 Diabetes.

65. A pre-diabetic condition reference expression profile, comprising a pattern of expression levels of one or more DBMARKERS detected in one or more subjects who are not diagnosed with or identified as suffering from a pre-diabetic condition.

66. A Type 2 Diabetes subject expression profile, comprising a pattern of expression levels detected in one or more subjects diagnosed with or identified as suffering from type 2 Diabetes, are at risk for developing type 2 Diabetes, or are being treated for type 2 Diabetes.

67. A pre-diabetic condition subject expression profile, comprising a pattern of expression levels detected in one or more subjects diagnosed with or identified as suffering from a pre-diabetic condition, are at risk for developing a pre-diabetic condition, or are being treated for a pre-diabetic condition.

68. A kit comprising DBMARKER detection reagents that detect one or more DBMARKERS, a sample derived from a subject having normal glucose levels, and optionally instructions for using the reagents to generate the expression profiles of any one of claims 64-67.

69. The kit of claim 68, wherein the detection reagents comprise one or more antibodies or fragments thereof, one or more aptamers, one or more oligonucleotides, or combinations thereof.

70. A pharmaceutical composition for treating type 2 Diabetes or a pre-diabetic condition in a subject, comprising a therapeutically effective amount of one or more DBMARKERS
or a metabolite thereof, and a pharmaceutically acceptable carrier or diluent.

71. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises SEQ ID NO:1.

72. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises at least 5 contiguous amino acid residues of SEQ ID NO:1.

73. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises at least 10 contiguous amino acid residues of SEQ ID NO: 1.

74. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises at least 15 contiguous amino acid residues of SEQ ID NO:1.

75. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises at least 20 contiguous amino acid residues of SEQ ID NO: 1.

76. The pharmaceutical composition of claim 70, wherein the DBMARKER
metabolite comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1.

77. A pharmaceutical composition consisting essentially of SEQ ID NO: 1 and a pharmaceutically acceptable carrier or diluent.

78. A method of treating type 2 Diabetes or a pre-diabetic condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 70 or claim 77.

79. The method of claim 78, wherein the subject has previously been treated for the type 2 Diabetes or the pre-diabetic condition.

80. The method of claim 78, wherein the subject has not previously been treated for the type 2 Diabetes or the pre-diabetic condition.